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of Malignant Glioma Jere T. Pikkarainen
Avidin-Biotin Technology 
and Targeted Treatment 
of Malignant Glioma
Glioblastoma multiforme is the most 
malignant brain tumor. Its treatment 
is hindered by the side-effects caused 
by the systemic chemotherapy. By 
targeted therapy, treatment is guided 
specifically into the tumor. This the-
sis aimed to develop a new targeted 
administration method using avidin-
biotin technology. Avidin-fusion 
protein was characterized in several 
targeting and imaging studies. The 
results showed that targeting offers 
























































































































































Glioblastomamultiforme (GBM) ismalignant tumor of glial cells, which are supporting
cells responsible for theupkeepofhomeostasis, the formationofbloodbrainbarrier and
themechanisticsupportofnerves.GBMisthemostfrequentprimarybraintumorandthe
mostmalignantneoplasmofastrocyticorigincomprising1215%ofallintracranialand60




onlyminorityof thedosagewill reach the tumor.Thiseventually leads to theuseof less




Avidinbiotin technology is basedon the endogenousproperty of avidin to effectively
bindbiotinwiththehighestaffinityofanytypeknownnoncovalentbinding(Kd=1015M).
Avidin,arathernontoxicproteinfoundonlyinbirds,reptilesandamphibians,isaperfect
tool for targetingmolecules inmammals as there areno interfering endogenous avidins.
Biotin, a common coenzymewithmultiple functions ofmammalian cells, can relatively






In this study, the function of the avidinfusion protein was characterized in several
targetingandimagingstudiesinvitroandinvivo.Theviralvectorsareproducedwithhigh
yieldsandarerelativelynontoxictothehostcells.Furthermore,theavidinfusionprotein
was shown to efficiently bind biotinylated products and take up them. In addition the
receptor was recycled back to the cell surface. The avidinbiotin technology was
successfully utilized in targeting biotinylated drugfilled nanoparticles into cancer cells.
Avidinbiotin technology was also used to target radiotherapy that led to improved
survivalofratsinanimmuncompetentmalignantgliomamodel.Targetingwiththeavidin
fusionprotein isa robustsystemthatcanbeused in twosteppretargeting therapiesand
canpotentiallyoffersignificantimprovementsformulticomponentpretargetingstrategies.
















































































Glioblastomamultiforme (GBM) kuuluu aivojen astrosyyttisolujen kasvaimiin, glioomiin.
Astrosyytitovataivojentukikudossolujajanemm.toimivathermokudoksenmekaanisena
tukena, osallistuvat homeostaasin ylläpitoon sekä ovat mukana muodostamassa veri
aivoestettä. GBM on yleisin pahanlaatuisista glioomista. Kaikista  kallonsisäisistä
kasvaimista noin 1215%  ja noin kolmasosassa astrosyyttisistä kasvaimista ovatGBM:a.
Lukuisista tutkimuksista huolimatta GBM:n hoito ei juurikaan ole kehittynyt viimeisten
vuosikymmenten aikana. Potilaiden keskimääräinen elinikä diagnoosin jälkeen on vain
noin 15 kuukautta ja 5vuotis eloonjäämisennustekin on vain 9,8%.  Yksi suurinGBM 
hoidonongelmaonsolusalpaajalääkkeidensysteemisenannostelunaiheuttamatsivuoireet,
sillä lääkeaineet vaikuttavat epäspesifisesti kaikkialla kehossa eikä ainoastaan kasvaimen
alueella. Tämän seurauksena hoitoa tulee rajoittaa tai pahimmassa tapauksessa lopettaa
kokonaan potilaan hyvinvoinnin turvaamiseksi, mikä mahdollistaa kasvainsolujen
selviämisen. Kohdennetun hoidon avulla lääkeannos voitaisiin ohjata spesifisemmin
kasvaimeenjanäinkohdistaalääkkeensytotoksinenvaikutussinneminneseolialunperin
tarkoitettu. Kohdennetun hoidon avulla voidaan huomattavasti parantaa lääkehoidon
taloudellisuutta,tehokkuuttajaturvallisuutta.
Avidiinibiotiini teknologiaperustuuavidiininominaisuuteen sitoa läheskovalenttisen
sidoksenvoimakkuudellaitseensäbiotiinia(Kd=1015M).Avidiinionlintujen,matelijoiden
ja sammakkoeläinten munista löytyvä proteiini, jonka uskotaan toimivan puolustajana
vapaatabiotiiniäkäyttäviämikrobejavastaan.BiotiinionvesiliukoinenvitamiiniB7, joka
toimii luonnollisena koentsyyminä monissa eri solujen prosesseissa. Biotiini voidaan
suhteellisenyksinkertaisesti lisätä läheskaikkiinmolekyyleihinvaikuttamattaolennaisesti
ko. molekyylin varaukseen, toimintaan tai kokoon. Näin muodostettua biotinyloitua
molekyyliä voidaan tehokkaasti hyväksikäyttää kohdennettaessa lääkeaineita
kasvainkudokseenavidiinibiotiiniteknologianavulla.
Olemme tutkineet fuusioproteiinia, joka koostuu solujen pinnalla ilmenevästä LDL




biotiini teknologiaa käytettiin hyväksi kohdentamaan sytosalpaajilla täytettyjä
nanopartikkeleita syöpäsoluihin sekä kohdentamaan radioterapiaa eläinmallissa
aikaansaaden pidennetyn eliniän. Fuusioproteiini mahdollistaa ns. kahden askeleen
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According to theWorldHealthOrganization (WHO) cancer is considered as the leading
causeofdeathworldwideaccountingfor13%ofalldeaths.Cancerincidenceisincreasing
every year due to the aging population and increasing cancerassociated lifestyles. The
AmericanBrainTumorAssociation estimates that 64,530newprimarybrain tumor cases
will havebeendiagnosedduring 2011 in theUnitedStates alone andof thesemalignant
gliomasarethemostcommonsubtypecomprising31%ofallprimarybraintumors.More
than half of all glioma patients will unfortunately be diagnosed for GBM, an astrocytic
tumor considered to be the most malignant and frequent primary brain tumor with an
overallglobalincidenceof34newcasesper100,000population,ameansurvivaltimeafter
diagnosisoflessthan15monthsanda5yearsurvivalrateoflessthan9.8%(Stuppetal.,
2009). The current treatment of GBM is considered as palliative, i.e. a noncurative
improvement in thequalityof life, thatconsistsofaggressiveconcomitantexternalradio
andsystemicchemotherapyregimensfollowedbyanadjuvantsystemicchemotherapy.As
theGBMgrowsinahighlydiffuseandinvasivepattern,surgicalresectionofthetumoris





chemotherapeutic drugs is an extremely toxic regimen. It is based on on characteristic
functionofproliferatingtumorcellstoendocytosemoresubstancesfromtheextracellular
space or circulation than healthy brain paranchyme. In addition, due to the existence of
mutations that are commonlypresent inmalignant cells, these cells are considered to be
lesseffective inrepairingtheadditionalmutationscausedbythetreatmentregimen, thus
making them more sensitive to the treatment than healthy cells (Sompayrac, 2004).
However, the limiting factor in every type of cancer treatment is the severe side effects
causedbythecytotoxicitytothehealthycellsandorgans.
Targeted therapy is a field of cancer research that focuses on investigating different
therapies and methods that can guide the effects of antineoplastic treatments
simultaneously into the tumor tissue andaway fromhealthy, offtarget tissues.Targeted
therapy can be achieved by increasing the affinity of the drug for the tumor tissue or
decreasingitsuptakeintoofftargettissue.Inaddition,thedrugcanbemodifiedsothatit
isactiveonlyunderspecificconditionssuchasthosepredominantlypresent incancerous
tissues and in that way creating a treatment modality that has its effect mostly in the
malignanttumortissue.
Targeted therapywas first suggested in 1930s by Paul Ehrlich under the term magic
bullet,describingtheactionofantibioticstofightdiseasecausingmicrobesastheytargeted
thecauseofthedisease,yetsparedthehealthycells(StrebhardtandUllrich,2008).Inthe
1970s monoclonal antibody (Ab) technology was discovered enabling the production of
highly specific targeting moieties (Kohler and Milstein, 1975). Abs were initially linked
chemicallytoantineoplasticmoleculesbutthisrequiredcomplexchemistry,whichcaused
problemswithstabilityandaggregationof thecompounds.However, the introductionof
theavidinbiotintechnologyresultedinaplethoraofeasilyproducedandstableantibody
drug molecule combinations (Wilchek and Bayer, 1990). The avidinbiotin system is
characterizedbythespecificandhighaffinitybindingbetweenavidinandbiotinmoieties.






avidin moiety expressed on the cell membrane after viral transduction of the cell
(Lehtolainenetal.,2003,Leschetal.,2009).Therationalebehindtheavidinfusionproteinis
toexploittheinherentabilityoftheLDLRtoinduceendocytosisonceactivatedbybinding
of a biotinylated molecule to the avidin moiety in the extracellular side of the cell
membrane. Therefore, the avidinfusion protein enables the targeting of various
biotinylatedmoleculesintothetumortissueafterlocalgenetransferofthecells.
Inthisthesis,thenoveltargetedtherapiesweredevelopedtobeusedinthetreatmentof
GBM.Itdescribes theuseofanovelavidinfusionprotein for invitroand invivo therapy








2.1 CLASSIFICATION OF BRAIN TUMORS 
Areliable classification system is crucial in thediagnosis of gliomas as it determines the
modeoftreatmentforthedisease.Gliomasoriginatefromnonneuronalglialcellsnormally
functioning as maintainers of homeostasis, producers of myelin and providers of both
supportandprotectionofneurons.Gliomasareusuallyclassifiedintogroupsaccordingto
glialcelltypeortumorgrade.However,tumorsofthebraincanalsobeclassifiedbytheir




Gliomas can be classified as ependymomas, astrocytomas, oligodendrogliomas ormixed




and perivascular pseudorosettes. Ependymomas account for about 5 % of all adult
intracranial gliomas, but are slightly more common in childhood gliomas, where they
comprise approximately 10 % of all cases. The majority of these tumors (85 %) are
myxopapillaryependymomasthatarecharacterizedasslowgrowingWHOgradeItumors.
Surgicalremovalisfavoredinthetreatmentofependymomas.However,unreachableand
malignant types canbe treatedwith radiotherapyor combination treatment consistingof
radiotherapyandchemotherapy.
Astrocytomas originate from starshaped glial cells, astrocytes, and are the most
common type of gliomas representing up to 75 % of all neuroepithelial tumor cases.
Astrocytomasaremostcommonlyfoundinthecerebrumbuttheycanoccurinanypartsof
thebrain,evenoccasionallyinthespinalcord.Astrocytomasdonotshowthetendencyto
spread outside of the brain. Astrocytic tumors can be further divided into two separate
classes; tumors with narrow zones of infiltration and those with diffuse zones of
infiltration.
Oligodendrogliomas are thought to originate from glial precursor cells called
oligodendrocytes.Oligodendrogliomasoccurprimarilyinadults(9,4%ofallCNStumors),
however, theyalsocanbeencountered inchildren (4%ofallprimaryCNStumors).The
morphology of oligodendrogliomas is that those are enlarged, round cellswith compact
nuclei anda small amountof eosinophilic cytoplasm.Tumors alsohave avasculature of
fine branching capillaries and a tendency to cluster around the neuronswhen invading
greymatter.Theclassificationofoligodendrogliomasrequiresabiopsyas theycannotbe
differentiatedfromotherlesionssolelybytheirclinicalsignsorradiographicappearance.
Mixed gliomas display characteristics of different classes of glial tumors, such as
oligoastrocytomasthatresemblebotholigodendrocyteandastrocyteoriginatedtumors.
2.1.2Gradingofgliomas
The most commonly used method to grade tumors of astrocytic origins is the WHO
gradingsystemthathas fourgrades forclassificationof tumoraggressivenessbynuclear
atypia, mitotic figures, microvascular proliferation and focal pseudopalisading necrosis
(Nakamura et al., 2007, Collins, 2004). Grades I and II are considered to be well





potential and complete resection of these localized tumors is usually possible. Grade II
tumors are generally considered as infiltrative by nature and have an atypical cellular
structure. Some tumors, such as diffuse astrocytomas,may progress to higher grades of
malignancy.GradeIIItumorsdisplayhistologicalevidenceofmalignancyincludingatypia,
mitotic activity and anaplasia. Grade IV tumors are cytologically malignant, mitotically
activeandexhibitmicrovascularproliferation.Thelesionsarepronetonecroticregionsand
are often associated with rapid pre and postoperative disease evolution and a fatal
outcome.
2.2 GLIOBLASTOMA MULTIFORME 
GBM is the most frequent primary brain tumor and the most malignant neoplasm of
astrocytic origin.WHO grade IV tumor includes histological findings of nuclear atypia,
cellular pleomorphism, mitotic activity, vascular thrombosis, microvascular proliferation
and necrosis. The de novomanifestation of primaryGBMwithout precursors is typically
foundinadultsandinthecerebralhemispheres,whereassecondaryGBMusuallydevelop
slowly fromdiffuse astrocytomas or anaplastic astrocytomas.Due to the highly invasive
natureofGBMs, complete resection isvirtually impossible,which leads to ahigh rateof
recurrencesandlowoverallsurvivalinthesepatients.
2.2.1Epidemiology
The incidence of primary GBM is 3.55 cases per 100,000 in Europe andNorth America,
while secondary GBM are much more rare, having an incidence of only 0.2 cases per
100,000(OhgakiandKleihues,2007).AlthoughGBMcanmanifestatallages,mostcasesof





females (m/f ratio 0.17) (Godard et al., 2003). PrimaryGBMare characterized by a rapid
onsetandprogressof thedisease,due to itsdenovomanifestationandaggressivenature.
ThemedicalhistoryofprimaryGBMpatientsisgenerallyshort,lessthan3monthsin68%




Therearevariousgeneticalandenvironmental factors thatcontribute to increasedriskof
GBM. Genetic and/or hereditary diseases, such as neurofibromatosis (NF), tuberous





mutation in theMerlin tumor suppressorgene leading to increased riskofbrain tumors.
Tuberous sclerosis is amultisystem genetic disease characterized bymutations in tumor
suppressorsTSC1,TSC2,orboth,leadingtogliomagenesis(Jahagirdaretal.,2011).Thetwo
autosomal dominant diseases, Von HippelLindau and LiFraumenis syndrome have
mutations invHLandp53tumorsuppressors,respectively(Olivieretal.,2003,Blouwet







aggregation of glioma incidence accounting for 2  5 % of all cases. The tendencies to
develop disease have been studied in glioma prone families suggesting an autosomal
dominantinheritancein1%ofthecaseswhencomparedtothecontrolcohort(Malmeret
al.,2001,Malmeretal.,1999,Hemminkietal.,1999).
Several environmental factors are suspected as increasing the risk of inducingglioma.
However, for none of them, with the exception of ionizing radiation, has a clear causal
relationship beendemonstrated (Schwartzbaum et al. 2006). Israeli childrenwere treated
with16Gydosesofradiationduetotineacapitis,aninfectionofthescalp(Saengeretal.,
1960).Duringfollowupofthechildren,asignificantlyincreasedriskofmeningiomaswas







According to the monographs of the International Agency for Research on Cancer
(IARC, 19722012, volumes 1102), the effects of almost one thousand agents have been
studiedontumorsinhuman,ofwhichhalfarelistedascarcinogensand0.1%havebeen
suggested tohaveaweakassociationwithCNS tumors inhuman. In addition, there are
several known agents, such as aflatoxin B1, acrylamide, nitrosoureas, procarbazine,
dacarbazine and dimethyl sulfate, that are known to be able to induce brain tumors in








of fruits, fresh vegetables and vitamin C is believed to be inversively associated with




2012). Although, cytomegalovirus is accepted to have an modulatory role in malignant




braindoes not have anypain receptors, the symptoms caused by brain tumors typically
appearatavery latestageof thedisease,at tumorsizesof3060g (DelSoleetal.,2001).
Brain tumors are considered lethal when the mass of the lesion exceeds 100 g. The
symptoms of central nervous system malignancies are caused by compression and
replacementoffunctionalbrainareasanddependgreatlyonthelocationofthetumor.For
example, a tumor in the spinal cord can cause numbness in the extremities, pain and
weakness while tumors in optic nerve can result in loss of vision. However, the most
commonsymptomsofGBMsareepilepticseizureswhichoccurinonethirdofthepatients,






GBM lesions are highly delineated showing peripheral proliferation and
pseudopalisading necrosis, a hypercellular tumor mass with a central area of necrosis,
which can occupy up to 80 % of the lesion (Louis et al., 2007). Tumor cells are
hyperchromatic, pleomorphic and have extensivemicrovascular activity suggesting high
proliferationrate,malignancyandincreasedinvasiveness.Hemorrhagesarealsofrequently
present, displaying several red and brown loci of recent and remote activity within the
tumor.Inaddition,cystscontainingliquefiednecrotictumortissuecanbefoundinGBM.











of molecular interaction between the malignant cell and the brain parenchyma. There,
tumorcells firstestablisha receptormediatedadhesion to theextracellularmatrix (ECM)
proteins of the brain parenchyma via integrins. Second, tumor cells can secrete several
matrixdegrading proteases, such as metalloproteinases, serine proteinases and cysteine
proteinases,whichareenzymescapableofdestoyingtheECMproteins,therebycreatingan
open space. Tumor cells can then actively move into this newly formed space by
rearrangement of cytoskeletal structures and membrane synthesis (Giese andWestphal,
1996,DemuthandBerens,2004).
2.2.5Diagnosticmethods
The presence of gliomas is primarily diagnosed with noninvasive methods such as
magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) or
modalitiesbasedoncomputedtomography(CT,SPECT/CTandPET).Theseallowimaging
oforganicanatomicchangeswithinthepatientandthedetectionofchangesinmolecular
function (Table 1). Nevertheless, a histological analysis of the tumor biopsy sample is
usually required to confirm the exact type and grade of the tumor. GBM is most often
diagnosed in the subcorticalwhitematter of cerebral hemispheres, frequently infiltrating
adjacent lobes and the contralateral hemisphere via the corpus callosum. Lesions
commonly are localized to the frontal lobe (40 %), but other lobes are also affected
(temporal29%,parietal14%,deeperstructures14%andoccipital3%)(Larjavaaraetal.,
2007). GBM rarely localizes in cerebellum or spinal cord, and intraventricularGBMs are




Direct signsofgliomas in thediagnostic imagesare thehighwater content, regressive
eventsandthevasculararchitecture(DelSoleetal.,2004).Since6090%ofthecelliswater,
a rapidly growing cellular lesion has a higherwater content than the surrounding brain
parenchyma. Thewater content of a lesion is important factor in tumor grading as high
grade tumors also tend to have a low nucleustocytoplasm ratio in comparison to low
grade tumors as well as a higher risk of vasogenic edema surrounding the lesion.











is attributable to the tumor growth within the limited cranial space and manifests as
displacement and destruction of other parts of the brain. Tumor cells release proteases
whichincreasethepermeabilityofproteinsthroughthebloodbrainbarrier(BBB)andinto
the extracellular space which leads to osmotic edema that further displaces tissue,
ultimatelyleadingtolossofbloodflowanddeath.

Table 1. Imaging modalities used in glioblastoma diagnostics and in both clinical and research 
settings. (modified from Beckmann, 2006). 
 
Modality Basis Resolution Type Description 
MRI NMR 0.1 – 1 mm A, F High contrast and spatial resolution in soft 
tissues, multiple sequences for functional 
imaging 
MRS NMR 0.1 – 1 mm Me, Mo Specific determination of different metabolites 
and their quantity within the tissues 
CT x-rays 0.05 – 0.5 mm A, F Relatively fast and cheap, high contrast in hard 
tissues 
SPECT -rays 1 – 8 mm F Multitracer modality 
PET -rays 1 – 4 mm F, Me, Mo High sensitive, single tracer modality 






tissues within the body as well as between soft and hard tissues. MRI is based on the
interactionbetweenastrongmagneticfield(from<1Tto12T)andnuclearmagnetization
of certain atomic nuclei within the body (Raty et al., 2007b). Nuclei with quantum
mechanicalpropertyofspin,suchas 1H, 2He, 3He, 23Naand 31P,alignandresonate in the
magnetic field allowing them to absorb energy from a radiowaves and consequently to
align to a higher state of energy.After termination of the radiation, the spins recover to
theirinitialalignmentinaprocesscalledrelaxation,inducingafreeinductiondecay(FID)





The golden standard of anatomical imaging is gadolinium enhanced T1weighted
sequence, where GBM is seen as a hypointense mass. Contrast agents increase the
differences in areas where the BBB is disturbed, highlighting leaky vasculature (Dillon,





can mask the actual GBM signal, a fast fluid attenuated inversion recovery (FLAIR)
sequencecanbeusedtonullifyfluidsignalfromedema(Epsteinetal.,1995).
MRI can also be used to image the vasculature and bloodflow in GBM. In perfusion
weighted imaging,MRIcanbeused tomap themicrocirculationandvesselpermeability
usingT2*sequencewith rapidbolusof contrastagent.Acquiredsemiquantativevalueof
relative cerebral blood volume (CBV) can be analyzed from the image. CBV has been
shown to correlate with the amount of capillaries (Sugahara et al., 1998). However, a
disturbed BBB (e.g. due to medication or inflammation) may increase signal in CBV
suggesting erroneously a higher grade of tumor. Therefore, the potential bias in
measurementshouldbeacknowledgedandcorrectedmathematicallyorhavebackground
valuesdeductedwithpredosingofcontrastagent.
Diffusion weighted imaging (DWI) maps the movement of water within the tissues.
Brownianmovement,therandomdiffusionofwaterduetothermalenergy,isaffectedby
structures, viscosity and tortuosity of extracellular space. As the mass effect, treatment,
proliferation of GBM and various other issues can change the tumor structure, cellular
density,cytoarchitectureandwaterhomeostasis,DWIcanbeusedtoimagethesechanges
(Brunberget al., 1995).DWImaps themovementofwater regardlessof itsdirectionand





Magnetic resonance spectroscopy (MRS) is amethod for quantative estimation of key
metaboliteswithinthetissues(Nelsonetal.,1997).Themostcommonlyidentifiedpeaksin
GBMarecholine,creatineandNacetylaspartate(NAA).Cholineisubiquitouslyfoundin
cell membranes and an increase in choline levels is indicative of membrane synthesis,
which has been shown to correlate with proliferation of the cells as shown by Ki67
stainings(Barbarellaetal.,1998).Creatineisanorganicacidthatsuppliesenergyforcellsat
aconstantrate,andthereforeitiscommonlyusedasareferencevalue.However,inGBM,
creatine peaks can be usually found outside the tumor indicative of infiltration.NAA is
foundonlyinneuronsandisthereforeamarkerofnormalneuronalfunction(Isobeetal.,
2002). Other metabolites which can be quantified in MRS are myoinositol, glutamate,
glutamine (astrocytic markers), lipids (membrane breakdown/necrosis) and lactate
(anaerobicglycolysis/necrosis)(Waleckietal.,2003,Kueseletal.,1994,Castilloetal.,2000).
SmalllesionscannotbeimagedwithMRSinaclinicalsettingbecauseofthepoorsignalto




Computed axial tomography (CT) is a noninvasive imaging method based on Xray
imagestakenaroundthepatientinasingleaxisofrotation(Dendy,1999).Theseindividual
2Dimagescanthenbereconstructedintoa3Dimageofthepatient.CTprovidesexcellent
resolution between hard and soft tissues of the body and has a moderate resolution
betweensofttissuesbutitisnotasgoodasMRI(MassoudandGambhir,2003,DelSoleet
al.,2001).ItcanbeusedasaninitialevaluationofsuspectedGBMasitisfasterandcheaper
thanMRI. Furthermore, CT is a useful diagnosticmethod if the patient has implantable
medicaldeviceswhichexcludeMRIprocedures.Thesedevicescanbecardiacpacemakers,
ferromagnetic vascular slips or nerve stimulators. In noncontrast CT, the lesions are
presented as an isodense or hypodense masses with central hypodensity (necrotic core)






still regarded as a moderate to high radiation diagnostic tool (Brenner and Hall, 2007).




Gammaradiationemittedfromaradionuclide fromwithin thepatient isrecordedwitha
gamma camera. A collimator is used to absorb nondirectional gamma rays thereby




tovisible light in the scintillationcrystalswithin thedetectors.Visible signalsare further
converted by photomultiplier tubes (PMT) into electric signals that contain information
aboutthepositionandenergyofthedetectedgammarays.Therecordeddatacanthenbe
processedandreconstructedintoavisualimage.Sincetheenergyoftheemissionofeach
radionuclide is known, SPECT imaging can be done with multiple radiotracers
simultaneously.SPECTimageisusuallyfusedwithanatomicalCTimages(SPECT/CT)to
formamoredetailedpictureof thepatientsbrain (Ratyetal.,2007a).Thehalf lifeof the
radionuclides used in SPECT varies from tens of minutes to days, which provides the
possibilitytodofollowupscanswithoutneedingnewinjectionsofradionuclide.Labeling
of a wide range of endogenous molecules with these radionuclides is relatively
straightforward and does not need highly specialized radiochemistry equipment or
expertise.
The radioligands used in the diagnosis of GBM have specific uses. For example,
potassiumanalogue201Ticannotdiffuse intothebrain if theBBBis intactandis takenup
onlybyviablecellsbutnotnecrotictissueornonproliferatingglialcells(Andoetal.,1987,
Black et al., 1989). 111InPentetreotide or octreotide binds to those tumor cells with
somatostatin receptors (Bakker et al., 1991). 123Ialphamethyltyrosine is a labeled amino
acid thatusesa specific aminoacid transporter topass through theBBBand is takenup
morebytumorcellsthanbynormalbrainparenchymaasitcompeteswithnaturalLamino
acids (Benard et al., 2003). Some studies suggest that htere is  20 % volume boost for
radiation therapy planning with 123Ialphamethyltyrosine versus the MRI due to this
specificity(Grosuetal.,2002). 99mTcSestamibi,originallyusedinmyocardiumimaging,is
takenupdepending on the blood flow, plasma andmitochondrialmembranepotentials,
angiogenesisandtissuemetabolism(Maublantetal.,1993,DelmonMoingeonetal.,1990).
It isalsoa transport substrate forPglycoprotein,anenergydependenteffluxpump,and
thereforemayprovide evidence for activedrug resistancemechanisms (Hendrikse et al.,
1999).
2.2.5.4Positronemissiontomography
Positronemission tomography (PET) isan imagingmodality thatdetectspairsofgamma
rays emitted indirectly by positron emitting radionuclides such as 18F, 13N, 15O and 11C.
Theseradionuclidesundergoapositronemissiondecayinwhichtheyemittheantimatter





basedon the simultaneousor coincidentaldetectionof apairofphotons.Becauseof this
pairbaseddetectionof theevents, collimatorsarenotneeded inPET imaging,making it






multitracer imaging cannot be performed in PET, because all annihilations occur at 511
keV,thusmakingseparationbetweenradionucleotidesimpossible.
Depending on tumor and/or application, increased activity of glucose transporters,
aminoacidsornucleosidesandexpressionofhexokinaseorthymidinekinasecanbeused
in PET imaging (Klasner et al., 2010, Dhermain et al., 2010). The most commonly used
tracer, 2[18F]fluoro2deoxyDglucose (18FFDG), is a glucose analogue. It is taken into
the cells by glucose transporters and phosphorylated within the hexokinase pathway.
However, it is not metabolized in the time span needed for radiodecay of 18F that
substitutesforthehydroxylgroupinglucose.Phosphorylationofthemoleculepreventsit
from leaving the cell, making 18FFDG a suitable tracer for glucose distribution and
phosphorylation in thebody.As tumorcellsshowoverexpressionofglucose transporters




FET) are more sensitive tracers than the glucose analogue FDG and yield higher
concentrations into tumors as they take advantage of Ltype amino acid transporters






thymidine kinase 1 (TK1),which is an enzymepresent at high levels in rapidlygrowing
cells,intofluorothymidinemonophosphateresultsinintracellulartrappingofthemolecule




Despite thedevelopmentof imagingmodalities, thehistologicalanalysisof tumorbiopsy
tissue isanessentialpartofefforts toestablish tumorgrade.Thebasichaematoxylinand
eosin staining (H&E) can be used when tissue sample is assessed for nuclear atypia,
mitosis,endothelialproliferationandnecrosisstatus(DunbarandYachnis,2010,Bratetal.,
2008).Additionally, immunohistochemistrycanbeveryhelpful indeterminingthe tumor
phenotypeassensitiveAbsagainstmanytumorspecificoroverexpressedantigens,such
as glial fibrillary acidicprotein (GFAP), epidermal growth factor receptor (EGFR), repair
enzyme activity, such as O6methylguanineDNAmethyltransferase (MGMT) or
proliferationstate,suchasKi67,arewidelyavailable.
2.2.5.6Pseudoprogressionandpseudoresponse





al., 1986). However, there are some studies indicating that some advanced imaging
parameters,suchasCBV,areabletodistinguishpseudoprogressionfromarecurringtumor





Pseudoresponse is another imaging artifact related to antiangiogenic treatments of
GBM.Althoughantiangiogenictherapystabilizestheleakyvesselsandtherebydecreases
thevasogenicedema,itmaynotnecessarilyhaveanyeffectonthetumoraggressivenessor





Diseaseprogression fromasingleastrocyteorprecursorcell into lifethreatingmalignant
gliomarequiresmultiplegeneticalterationsincludingchangesintheDNAsequence,copy
numbers,chromosomalarrangementsandproteinmethylationstatusimpairingbothtumor




10 as well as mutations in epidermal growth factor receptor (EGFR), phosphatase and
tensinhomology(PTEN)andTP53genes,secondaryglioblastomaarecharacterizedmainly
byfrequentmutationsintheTP53gene.
There are also several differences between the promotermethylation and in the RNA
andproteinpatternsofprimaryandsecondaryglioblastomas(OhgakiandKleihues,2007).
Although, current treatment protocol (see Chapter 2.2.7 for details) is used against both
typesofglioblastomas,thesemoleculardifferencesarehighlyimportantinresearchandin

































Figure 1. Common molecular pathways of tumorgenesis.The over-expression or amplification of 
several tyrosine kinase receptors induce cell proliferation that is normally controlled by PTEN 
inhibitory action. Wild-type p53 is responsible for several crucial functions in the cell including 
apoptosis and cell cycle regulation, and is autoregulated by MDM2 and ARF proteins. E2F 
regulates the transition from G1 to S-phase of the cell cycle. Its function can however be 
altered via mutations or amplifications of RB1, CDK4 or P16. 
2.2.6.1Growthfactorsandcellproliferation
EGFRislocatedonchromosome7encodinga170kDatransmembraneproteinresponsible
for interacting with extracellular ligands, such as EGF and TGF. EGFR takes part in
proliferativesignalingwithinthecell.EGFRisthemostfrequentlyamplifiedgeneinGBM,
involving approximately 40 % of primary GBMs (rare in secondary GBM) (Ohgaki and
Kleihues, 2005b, Ekstrand et al., 1992). Amplification of EGFR is also associated with
overexpression:7090%ofallGBMwithoverexpressionofEGFRalsohaveamplificationof
EGFR (Tohma et al., 1998). There are several variants of EGFRmutations found inGBM
patients,themostprevalentbeingEGFRvIII,foundin2050%ofGBM(Huangetal.,1997).
EGFR signaling results in phosphatidylinositol3kinase (PI3K) recruitment and
phosphorylation of phosphatidylinositol4,5biphosphate (PIP2) to PIP3, which then
activatesdownstreameffectormoleculesresulting incellproliferationandpromotingcell
survival(Mellinghoffetal.,2005).
Tumorsuppressorphosphataseand tensinhomology (PTEN) ismutated in1540%of
GBMcasesinalmostexclusivelyinprimaryGBM(Knobbeetal.,2002).PTENislocatedon
chromosome10q23.3whereitencodesaproteinwithacentraldomainhomologoustothe




(Steck et al., 1997, Maehama and Dixon, 1998). Consequently, functional PTEN protein





damage, cell death, differentiation and neovascularization (Bogler et al., 1995).Although
TP53 mutations are very common in secondary GBM (65 %) and almost in all cases of
precursor lowgrade lesions, they are less frequent in primaryGBM (28%) (Ohgaki and
Kleihues, 2007). The distribution and type of mutations differ between primary and
secondaryGBMspointingtodifferentmolecularmechanismsbetweenthesetwotypes.In
primary GBM, the mutations are equally distributed among the exons, whereas in
secondary GBM the majority of mutations (57 %) occur at codons 248 and 273 (17% in
primaryGBM).Inaddition,theG:CtoA:TtransitionsaremorefrequentinsecondaryGBM
(OhgakiandKleihues,2005b).
Murine double minute (MDM2) oncogene located at 12q14.3q15 encodes a 54 kDa
negative regulatory protein that binds to both, mutant and wildtype p53 proteins,
inhibiting the ability ofwildtypep53 to activatedownstreamcascades leading to tumor
suppression (Momand et al., 1992).Under normal conditions,wildtype p53 andMDM2
proteins form an autoregulatory loop, where the presence of the p53 inducesMDM2 to
regulatewildtype p53 expression anddegradation (Picksley andLane, 1993). Therefore,




P14ARF located on chromosome 9p21 encodes a tumor suppressor protein that directly
inhibits the function of MDM2 protein. This further releases p53 from the MDM2
regulation.Lossofp14ARF functionis frequent inGBM(nosignificantdifferencesbetween
primary and secondary GBMs) correlating with homozygous deletion or methylation of
p14ARFgene (Nakamuraetal., 2001a). In lowergradeprecursorGBMs,aboutone thirdof
p14ARFgenesarefoundtobemethylated.Itisworthnotingthattheexpressionofp14ARFis
regulatedbythewildtypep53,creatinganautoregulatorysystem,inwhichtheregulatory





family, inhibiting the cell cycle progression from theG1 to S –phase (Sherr andRoberts,
1999).ThepromotermethylationofRB1geneisfoundmorefrequentlyinsecondary(43%)
than in primary (14 %) GBMs (Nakamura et al., 2001c). However, RB1 promoter
methylation is not present in low grade precursor tumors, suggesting that this is a late
eventinastrocytomaprogression.
CDK4genelocatedonchromosome12q14isencodesaproteinbelongingtothecyclin
dependent kinase family. CDK4 and Cyclin D1 proteins form a complex that
phosphorylates RB1 protein, leading to the inability of RB1 to bind E2F family
transcriptionalfactorsandtherebytothereleaseofG1toS–phasecellcyclecontrol(Sherr
and Roberts, 1999). CDK4 gene is amplified in 15 % of high grade gliomas, especially
amongthosethatdonothavep16INK4agenedeletion.
P16INK4aonchromosome9p21encodesatumorsuppressorproteinabletobindCDK4
protein and inhibit the formation of CDK4/Cyclin D1 –complex therefore negatively
regulating G1toS –phase transition. Loss of cell cycle control can thus be caused by




well as overexpression or amplification of either CDK4 or RB1 proteins/genes). The





normal function of a whole gene is lost after additional mutations on the remaining
functioning allele. In many hereditary diseases, the increased probability of acquiring
cancer, is due to the initial mutation in one allele with which the patient is born. In
gliomagenesis,themostfrequentgeneticalterationisLOH10presentin60–80%ofGBM
(Fujisawa et al., 2000). Although the deletion of an entire copy of chromosome 10 is
possible,itismorecommonthatonlyportionsaremissing.Forexample,themostcommon









are part of the standard chemotherapeutic GBM regimens (Figul et al., 2003). Loss of
MGMT is causedbymethylationofpromoterCpG islands and is associatedwith longer
survivalinpatientstreatedwithTMZ(Estelleretal.,2000,Pazetal.,2004).Itispresentin
4575 % of GBMs (secondary GBM shows a higher frequency of methylation than the
primaryform)(Nakamuraetal.,2001b).PromotermethylationsofTP53,p14ARF,RB1and
TIMP3genes are also common inGBMs, slightly favoring secondaryGBMoverprimary
GBM(OhgakiandKleihues,2007).
2.2.7Currenttreatmentofmalignantglioma











surgical intervention must include also partial resection, biopsy or palliative treatment.
These modalities aim at improved survival, symptomatic control, cytoreduction and
histological diagnosis (Whittle et al., 1998,Hentschel andLang, 2003). The first resection
wasreportedalreadyin1884anddespitetheimprovementsinthesurgicalequipmentand
techniques, patient survival has improved only marginally since the 1970s (Pang et al.,
2007,AvgeropoulosandBatchelor,1999).
There are only a handful of publications examining the efficacy of surgical excision






GBM includes for example opening of any obstructions in CSF circulation causing
increasedintracranialpressure.Foraccuratehistologicalanalysis,thebiopsysampleshould
be large enough or taken from multiple sites within the tumor, as GBM is a highly







are not viable enough to undergomitosis.Although, radiotherapydates back to the late




The twodimensional external beam radiotherapy (2DEBRT) was the first GBM
radiotherapymodality;thisconsistedofsinglebeamirradiationofthepatientfromoneto
fourdifferentdirections,leadingtoahigherabsorptionofenergyintheoverlappingareas.
However, relativelyhighdosesof radiationwere required toachieveeffectiveuseof2D
EBRT, leading to serious side effects (Bucci et al., 2005). The improvements in imaging
modalities,suchasCTandMRI,made3Dexternalbeamradiotherapy(3DEBRT)possible
inmid1980s.As threedimensional imagingof the tumorbecomepossible, the treatment
planning could include axial anatomy and complex tissue contours and even include
irregular shapes of therapeutic regions. Although, this led to a far better therapeutic
windowinirradiationtreatment,oncologistswerestillgreatlylimitedintheactualdosing
of radiation, as they only selected the amount and direction of radiation beams to fully
enclosethetumor.Thecomputerthencalculatedtheneededdoseofeachindividualbeam
to achieve efficient treatment (direct treatment planning). The means to achieve further
controlofthetreatmentcamewithintensitymodulatedradiotherapy(IMRT)thatallowed
control the intensity of individual subsectionsof radiationbeambyuseof collimators as
calculatedby thecomputer. IMTR isan inversivelyplanned treatment, i.e. theoncologist
first decides the dosing of individual tumor areas and then the computer selects the
amount,direction and intensity of beams to accomplish the set goals. Still, amajor issue
thereinisthatthetumorandpatientareinconstantmovement,eithervoluntaryorvisceral
movements. Furthermore, the patient may lose weight and therefore have altered
geometrical dimensions or the tumor may shrink due to successful treatment. The next
generationof radiotherapyhave included the 4thdimension, i.e. time, into the treatment
planning. Imageguided radiotherapy (IGRT) is a hybrid treatment modality where
imaging modalities, such as CT, and treatment modality, such as IMRT, are performed
simultaneously.Realtimeimagingofthetumorduringthetreatmentmakesitpossiblefor
the computer to compare the data and make the necessary adjustments to treatment
planning depending on the changes seen in the images. IGRT is a step closer to




been shown to improve the survival of patients with tolerable treatmentrelated








by beams of particles made of quarks, such as protons, neutrons or positive ions (in
comparisontoelectronbeams).Thesamekindoflinearacceleratorcanbeusedtoproduce
beamsofvariousparticlesasisusedintheformationofXrays(RongandWelsh,2010).In
particle therapy,as theenergizedchargedprotons (orpositive ions)pass through tissues
they attract negatively charged orbiting electrons and pull them away from their orbits,
therebyinducingionizationwithintissues(lowLET)(Nayaketal.,2005).However,unlike
thesituationinXrayionizationwhenthebeamhasthehighestenergybeforecollidingand
being absorbed into tissues, the proton ionization energy increases as the velocity of the
protondecreasesand the interactionswith surroundingelectronsbecomemore common.
ThisphysicalpropertyisknownasBraggspeakcausedbybremsstrahlung,alossofkinetic
energyofachargedparticleduetointeractionswithanotherchargedparticle(Coutrakonet
al., 1991). This enables proton (or positive ion) to have maximal ionization at deeper
coordinates thanconventionalXraybased treatmentmodalities that couldbepotentially
usefulinthetreatmentofGBM.Someionsheavierthanprotons,suchascarbonions,cause
even more ionization than protons increasing their efficiency in the treatment of GBM.




interactions, such as boronneutron capture therapy (BNCT) (Calderon and Jensen, 1990,
Barth and Joensuu, 2007). HighLET radiation is considered to be 101000 fold more
ionizingthan lowLETdamage.TheprincipleofBNCTwasfirstpresented in1930s,after
the discovery of neutrons by James Chadwick. BNCTwas assessed for the treatment of
GBMlaterinthe1950sto1960sbutduetopoorresults,furtherstudieswerenotperformed
untiladvancesinboroncarriersoccuredinthe1990s(Joensuu,2011).BNCTisbasedonthe
ability of 10B to capture low energy neutrons causing a fission reaction producing 
radiation(4He)and7Linucleus.Asemissiondecayswithinafewmfromthesource,itis
a relatively local source of radiation affecting only the cells containing boron and their
imminent surroundings. The limiting factor in BNCT is the requirement for a nuclear
reactor as the linear accelerators used in conventional radiotherapy cannot produce
neutrons. In addition, the superficial localization of tumor is preferred as low energy
neutrons cannot penetrate deep into the brain and it is difficult to achive therapeutic
concentrationswithinthetumors.Themostcommonmethodforborontransportistouse
Lboronphenylalanine (BPA),which is an amino acid generally having higher uptake in
cancerouscellsthaninnormalbrainparenchyma.InGBMhowever,theuptakeofBPAcan
belowwithinthetumorduetohypoxicareassurroundingthenecroticcoreofthetumor.
However, as boron uptake is also low in healthy brain parenchyma, BNCT can be
successfully used to treatGBMpatients after relapsewith acceptable side effects even if
patients cannot tolerate further conventional radiotherapy (Kankaanranta et al., 2011).








surrounding tissues resulting in a steep falloff dose as distance to the radiation source
increases.Inaddition,lowdosebrachytherapymorespecificallytargetsthetumorcells,as













as autopsies of victims ofmustard gas attacks showedprofoundmyeloid and lymphoid
suppression (Goodman et al., 1984, DeVita and Chu, 2008). It was theorized that the
inhibitionoftheproliferationofsomaticcellsthatdividerapidlybymustardgascouldalso
beusedas a cancer treatment.The first treatmentswith some success, albeitwithonly a
transienteffect,wereagainst lymphomas.Currently, chemotherapy isamajorpartof the
treatmentprotocol especiallywhengiven in combinationwith radiotherapyand surgery.




Currently the most commonly used and effective chemotherapeutic agents for GBM
therapy are TMZ, bischloroethylnitrosourea (BCNU or Carmustine) and PCV
(ProcarbazineCCNUVincristine) (See and Gilbert, 2007, Parney and Chang, 2003). All,
except for Vincristine, which causes mitotic spindle dissolution, are cytotoxic DNA
alkylating agents that inhibit mitosis and cause cell death via apoptosis. TMZ has been
foundtobethemosteffectivetreatmentwhencombinedconcomitantandadjuvantRT(see
below, EORTC/NCIC clinical study) (Stupp et al., 2005, Stupp et al., 2009). TMZ is a
prodrug spontaneously hydrolyzing into 3methyltriazen1ylimidazole4carboxamide
(MTIC)atphysiologicalpH.MTICalkylatesseveralguanineresiduesinDNA,withtheO6
positionbeingthemostsignificant(Newlandsetal.,1997,AgarwalaandKirkwood,2000).
Although the formedO6mG isnot toxic to thecellsalone, ifnot removed, itwill lead to
mispairingofO6mGwith thymine.This induces futile repaireffortsbymismatch repair
proteins that canonly remove the thymine,butnot theculpritO6mG(Hegietal., 2008).
Eventuallythisleadstoapoptosis.However,itisworthnotingthatthetumorcellswithan
active MGMT can repair the alkylation of O6guanine thus inducing chemoresistance
againstTMZ treatment (Hegi et al., 2005,Zhanget al., 2011b,Panet al., 2012).Thereare
manyotherchemotherapeuticagentsavailable, suchasetoposide, irinotecan,carboplatin,
cisplatin and doxorubicin. However, these have not shown to be as effective and TMZ,
BCNUorPCVandarethereforeusedonlyinspecialoccasions,whentheuseoftheabove
mentioned drugs is not an option, for example due to cost or toxicity of the treatment
(Vitvitskyetal.,1992).
2.2.7.4CurrentstandardtreatmentofGBM
The landmark study for the current standard treatment ofGBMwas conductedbetween
August 2000–March2002by theEuropeanOrganization forResearchandTreatmentof
CancerBrainTumorandRadiotherapygroup(EORTC)andtheNationalCancerInstitute
of Canada Clinical Trials group (NCIC) with 573 patients being enrolled into an
international randomized multicenter phase III trial (85 institutions in 15 countries) for
concomitantandadjuvantTMZandRTtreatmentversusRTaloneinpatientswithnewly









cycles. As TMZ treatment causes an increased risk of opportunistic infections due to
lymphocytopenia,prophylaxisagainstPneumocysticcariniijieroviciiwasadministeredeither
with pentamidine or oral trimethoprimsulfamethoxazole. Furthermore, antiemetic
prophylaxiswithmetoclopramideor5hydroxytryptaminewas recommendedduring the
concomitantTMZphaseandrequiredduringtheadjuvantphase.
The EORTC/NCIC trial had a median followup of 28 months with a hazard ratio
indicating37%relativereductionintheriskofdeathwiththecombinationtreatment.The
mediansurvivalbenefitincomparisontoRTalonewasnotmorethan2.5months(14.6vs.
12.1 months). However, the trial succeeded to significantly increase late survival of the





During the RT period, both groups displayed similarly few infections, moderate to
severefatigueandthromboembolicevents.TheTMZgroupreported2patientdeathsasa
resultofcerebralhemorrhageduetothrombocytopeniaorothercoagulationdisorders.The
RTgroupdidnothaveanygrade3or 4hematological events,whereas theTMZgroups














important prognostic factor due to its ability of repair the damage caused by TMZ and
otheralkylatingchemotherapeuticagents(Ducrayetal.,2011).
2.3 NOVEL TARGETED TREATMENT OF MALIGNANT GLIOMA 
2.3.1Cancergenetherapy
Cancer treatment by gene therapy refers to the use of genetic material which can be
expressedasaproteinbythecellsandwhichcaninterferewithvariousfunctionsofcellsor
directly eradicate a cancerous cell. As tumors are often very resistant to conventional
treatment modalities and have a genetical background, the use of gene therapy as a
treatmentisveryattractive.Cancergenetherapycantakemanyforms,suchasreplacinga
defectivegenewithanormaloneorhinderingthefunctionofanoverexpressedprotein,or
augmenting the patients immune response against the tumor, forcing cancer cells to
undergoapoptosis, inhibiting furthergrowthbyblockingvascularizationorusingcancer
cellspecificoncolyticvirusestodestroythetumor.
So far, more than 1700 gene therapy trials have been conducted (Journal of Gene
Medicine,March2011,www.wiley.co.uk/genehterapy/clinical),ofwhichthemajority(64.5
%)arerelatedtocancer(Table2).Almosttwothirds(63.7%)ofthetrialshavebeendonein





threegene therapeuticproductshavebeenapproved in theworld.Twooncolyticviruses
for the treatment of head and neck squamous cell cancer are approved in China by the
ChineseStateFoodandDrugAdministration,ShenzhenSiBionoGeneTechsGendicineand
ShanghaiSunwaysH101 (Peng,2005Garber,2006) thatarebothselectivelyreplicating in
p53deficient tumor cells. Furthermore, in the Philippines RexinG, a tumor targeted
retroviruswith cytotoxic cyclinG1 transgene,mady by Epeius Biotechnologies has been
approved by the Philippine Bureau of Food andDrugs (Gordon andHall, 2010). In the
westernworld,Cerepro,areplicationdefectiveadenovirusexpressingHerpessimplexvirus
thymidinekinase(HSVtk)byArkTherapeuticsforthetreatmentofmalignantgliomawas
the pioneer product in cancer gene therapy (Immonen et al., 2004). However, Cerepro
received a negative opinion by European Medicines Agency (EMA) during late 2009
concerning the company’smarketing authorization application. Thus, the field of cancer












































Table 2. Gene therapy clinical trials in the world according Journal of Gene Medicine 
(www.wiley.co.uk/genmed/clinical) – updated March 2011 
TRIALS BY CONTINENTS TRIALS BY COUNTRIES USE IN CANCER TRIALS
Continent # % Country # % # %
America 1107 65.0 USA 1084 63.7 728 67.2 
Canada 22 1.3 13 59.1 
Mexico 1 0.1 1 100.0 
 
Europe 488 28.7 UK 197 11.6 126 64.0 
Germany 79 4.6 54 68.4 
Switzerland 50 2.9 27 54.0 
France 45 2.6 19 42.2 
Netherlands 27 1.6 18 66.7 
Belgium 25 1.5 17 68.0 
Italy 21 1.2 13 61.9 
Spain 13 0.8 9 69.2 
Sweden 8 0.5 2 25.0 
Poland 6 0.4 4 66.7 
Finland 5 0.3 1* 20.0 
Norway 4 0.2 4 100.0 
Austria 2 0.1 1 50.0 
Denmark 2 0.1 - - 
Czech Republic 1 0.1 1 100.0 
Ireland 1 0.1 - - 
Romania 1 0.1 - - 
Russia 1 0.1 1 100.0 
 
Asia 64 3.8 China 20 1.2 19 95.0 
Japan 19 1.1 12 63.2 
South Korea 13 0.8 6 46.2 
Israel 9 0.5 4 44.4 
Singapore 2 0.1 2 100.0 
Taiwan 1 0.1 - - 
 
Austrasia 30 1.8 Australia 28 1.6 10 35.7 
New Zealand 2 0.1 - - 
 
Africa 1 0.1 Egypt 1 0.1 1 100.0 
 
International 13 0.8 Multi-Country 13 0.8 5 38.5 
 





use of viral vectors that act as gene carriers. At themoment, viral vectors are themost
efficientandmostwidelyusedtypeofgenetransfertechniques.Themostfrequentlyused
vectors in cancer gene therapy are adenoviruses and retroviruses (Journal of Gene
Medicine,March2011,www.wiley.co.uk/genehterapy/clinical)comprisingmorethat40%






Table 3. Viral vectors used in the clinical trials worldwide according Journal of Gene Medicine 
(www.wiley.co.uk/genmed/clinical) – Updated March 2011 
ALL TRIALS USE IN CANCER TRIALS 
Vector # % # %
Adenovirus 402 23.6 305 75.9 
Retrovirus 351 20.6 194 55.3 
Naked/Plasmid DNA 316 18.6 182 57.6 
Lipofection 109 6.4 88 80.7 
Vaccinia virus 105 6.2 71 67.6 
Adeno-associated virus 81 4.8 18 22.2 
Poxvirus 66 3.9 53 80.3 
Herpes Simplex virus 57 3.3 55 96.5 
Lentivirus 38 2.2 11 28.9 
RNA transfer 27 1.6 26 96.3 
Flavivirus 8 0.5 - - 
Measles virus 6 0.4 5 83.3 
Saccharomyces cerevisiae 6 0.4 6 100.0 
Gene gun 5 0.3 5 100.0 
Lactococcus lactis 4 0.2 - - 
Listeria monocytogenes 4 0.2 3 75.0 
Salmonella typhimurium 3 0.2 3 100.0 
Transposon 3 0.2 3 100.0 
Escherichia coli 2 0.1 - - 
Sendai virus 2 0.1 - - 
Venezuelan equine encephalitis virus 2 0.1 2 100.0 
Vesicular stomatitis virus 2 0.1 2 100.0 
Newcastle disease virus 1 0.1 1 100.0 
Poliovirus 1 0.1 1 100.0 
Semliki Forest virus 1 0.1 1 100.0 
Shigella dysenteriae 1 0.1 - - 
Simian virus 40 1 0.1 1 100.0 
Streptococcus mutans 1 0.1 - - 
Vibrio cholerae 1 0.1 - - 













ADV attaches to the host cell by binding to the knob domain of the fiber protein to
coxsackievirus B and adenovirus receptor (Hackett, 2004). A specialized RGD (ArgGly
Asp)motifinthepentonbasetheninteractswiththeavintegrinmoleculewhichtriggersa
clathrindependentreceptormediatedendocytosisforinternalizationoftheADVparticles.
Once theendosome isacidified,viralparticlesescape into thecytoplasmbysomepoorly







consists of early (E1A, E1B, E2E4) and late (L1L5) genes. First transcriptional unit
expressedistheE1AgenewhichshiftsthehostcellintotheSphaseofthecellcycleviaRB
pathway and activates the remaining early genes. As the cell cycle regulation causes
accumulationofp53,whichinnormalconditionswouldleadtoapoptosis,E1Bblocksthe





The so called first generation adenoviral vectors have the E1 region deleted (E1)
leadingtoabolishedviralpromoteractivationandimpairedreplicationbutalsofreeingup
5.1 kb of space for transgenes (Imperiale andKochanek, 2004,Danthinne and Imperiale,
2000). Inaddition, thedeletionof theE3genewasabletofreeupanother3kbofgenetic
space, amounting to a total vector capacity of 8.1 kb (Verma andWeitzman, 2005). The
generation of replication competent adenoviruses (RCAs) was problem in the first
generationADVs, as homologous recombinationwith the complementing cell lineswith
existingE1regionsoccured.ThefirstgenerationofADVswasalsocharacterizedwithhigh
cellular immune response against the vector preventing any longterm applications.
Immunological problemswerediminished and size of transgene increased in the second
generationADVs by deletions of E2 and E4 regions (Gao et al., 1996, Armentano et al.,





disorders. ADVs infect dividing and nondividing cells, have broad host tropism and
transientgeneexpression. Inaddition,ADVscanbeproduced inveryhigh titersmaking





Tcell leukemiabovine leukemia viral groups aswell as spumaviruses and lentiviruses).
Due to transformingpotential, the first fivegroupsare characterizedasoncoviruses.The
latter three constitute complex retroviruses which have multiple splice acceptor sites in
theirgenomesthatincreasegeneticvariation.RVsaresphericalvirusesapproximately100









simultaneously releasing viral components into the cytoplasm. RVs have a characteristic
method of replication using reverse transcription of the viral RNA into linear double
strandedDNAandthesubsequentformationofpreintegrationcomplex(PIC)consistingof





and be integrated into the host genome (Gilbert and WongStaal, 2001). However,
lentiviruses(LVs)canactivelyenterthecellnucleusthroughthenuclearenvelopeandthus










virusandavian leukosisvirus,havebeenused in thegene therapy.However,due to the
leukemiadevelopingin5of11childrentreatedwithretrovirusesagainstseverecombined




LVs are complex viruses of theRetroviridea familydivided into 5 serotypes respective to
theirhostanimal(equine,sheep,goat,catandcattle).Themostwidelystudiedlentivirusis





vivo. Tat is a transactivator of transcription and rev regulates alternative splicingof viral
genes(Freed,2001).
AsHIV1causesacquiredimmunodeficiencysyndrome,amajorefforthasbeenputinto
removing all viral and nonessential sequences from the LV vector to hinder viral
replication and potential generation of replication competent lentivirus. Therefore, the
current third generation LV vectors are produced by cotransfection of four separate
constructsintoproducercells(3helperand1vector).Incomparison,thefirstgenerationof
LVswereproducedwiththreeseparateconstructsincludingpackagingconstructfreeofthe
packaging signal, env and the transfer vector RNA, without viral genes (Naldini et al.,
1996).Asregulatoryproteinsvif,vpr,vpuandnefwerenotnecessaryforgenetransfer,a
second generation of LV vectors had these additional regulatory proteins removed
(Zuffereyetal.,1997).AfurtherincreaseinthebiosafetyoftheLVvectorwasachievedin
the third generation by substituting the tatdependent transcription sequence with an
alternativeheterologouspromoterfromcytomegalovirusorRoussarcomavirusaswellas
deletingpartsofthe5longterminalrepeatsequencesformingaselfinactivatingLVwhere
viral promoter and enhancer elements are eliminated during integration (Zufferey 1998,
Verma1998,Delenda,2004).
LVs offer stable long term expression in both dividing and nondividing cells, with
optionaltransienttransductioniftheintegraseisremovedfromthegenome(Philippeetal.,
2006).  However, due to difficulties in the production of high titer batches and safety
concernsduetoinsertionalmutagenesis(Liuetal.,2006),LVshavebeenusedonlyin2.2%
of clinical trials. There have been several preclinical successes using LVs in treatment of
Alzheimer’s, Parkinson’s andHuntington’s diseases aswell as in immunodeficiency and
hematopoieticdisorders(Mortellaroetal.,2006,Brownetal.,2007,Lundbergetal.,2008).
2.3.2.3Alphaviralvectors
Alphaviruses (ALVs) belong to a genus of theTogaviridae family.Nearly 30 viral strains





and Strauss, 1994, Luers et al., 2005). ALVs are enveloped spherical viruses which are
around 70 nm in diameter containing a single stranded RNA genome of positive sense
withinanisometricnucleocapsid.ThegenomeencodesfornonstructuralviralproteinRep
that is further cleaved into nsP1, nsP2, nsP3 and nsP4 and structural proteins for
nucleocapsid(proteinC)andenvelope(precursorP62forproteinsE1,E2and6K).Manyof
the30differentviruses found inALVgenusareofgreat interest forgene therapydue to
theirbroadtropismandhighleveloftransgeneexpression.
ALVs infect host cells via endocytosis executed by interaction between host cell
membranereceptorsandenvelopeglycoproteinsE1andE2(StraussandStrauss,1994).As
theviralenvelopefuseswiththeendosomemembrane,theviralparticlesarereleasedinto
the cytoplasmwhere the replication takes place.Within the first hours of infection, the
unprocessed Rep protein synthesizes complementary negative sense RNA. Rep is then







ALVs vectored transgene expression is detected only hours after transduction and
expressionpeaksafter24–48hourspostinfection.SinceALVscausenearlycompletehost


























Baculoviruses (BV) are large rodshaped enveloped viruses measuring, 250300 nm in
length and 2550 nm in diameter, belonging to the large viral family of Baculoviridae
consisting of over 600 members (Airenne, 2009). BVs are divided into two genera;




nucleopolyhedroviruses (NPV), foundwith either a single orwith several capsids inside
the sameenvelope.Although,BVsare insectviruses, theyhaveabroad tropismandcan
enter cells of many species. However, they are not known to productively infect any
vertebrate animal cells. The most widely studied BV is Autographa californica multiple
nucleopolyhedrovirus (AcMNPV) (Miller, 1997). It has a circular double stranded DNA
genomeof80180kbpsencodingthemajorcapsidproteinsVP39,p80andp24togetherwith
minor structural andotherproteins, suchas envelopeglycoproteinGp64 (Braunagel and
Summers,1994).




are transported to nucleus by actin filaments where they initiate viral transcription and
produce new BV particles. These particles become bud from the cells during secondary
infection. As the infection spreads, activeODVproduction leads to cell lysis, eventually
killingthewholeinsect.AsBVsarenotknowntoreplicateinmammaliancells,butareable
toexpressthegenesundermammalianpromoters,theycanbeconsideredtoberelatively
safe viral vectors (Airenne et al., 2009). However, BVs are rapidly inactivated by the
complementsysteminserum,restrictingtheirefficientusetoimmunopriviligedareas,such




Poxviruses (PV) are large viruses of the Poxviridae family. PVs are divided into the
ChordopoxvirinaeandEntomopoxvirinaesubfamiliesaccordingto theirvertebrateandinsect
host preferences, respectively. Members of the latter groups have not yet been used as
vectors.ChordopoxvirinaeisfurtherdividedintoeightgeneraofwhichOrthopoxvirinaeisthe
mostwidely studied,namely theVariola (smallpox) andVaccinia strains.Generally,PVs
arebrickshapedenvelopedvirionsof200250nm indiameter containinga lineardouble
strandedDNAof130300kbswithahairpinloopateachend(Moss,2001).ThePVshave
averyvaried host range i.e. ranging from very broad to very specific, and the viral
replicationtypicallyleadstocelllysiswithin1224h.
Vacciniavirus (VV) has been used in multiple vaccination studies and programs to




been used in 6.2 % of clinical trials due to its broad host tropism, very high level of
transgene expression and large insert capability. Its lytic properties and tumor cell
selectivitymakeitapotentoncolyticvirus(Puhlmannetal.,2000).
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Herpes viruses (HVs) belonging to theHerpesviridae family and these virusesare able to
infectmost animal species (Roizman, 2001). Themostwidely studiedherpes virus is the
Herpessimplextype1(HSV1),aDNAviruswithdoublestrandedlineargenomeof152kb
whichissurroundedbyacapsidanda lipidenvelope.TheHSV1genomeencodesmore
than 80 genes many of which are dispensable freeing space for incorporation of large










into the host cell by physical or chemical methods. The use of nonviral vectors is
considered to be safer since this bypasses several problems relatedwith the use of viral
vectors,suchasoncogenicityandendogenousviralrecombinationandsomeimmunologic
issues.However,thepresenttechniquesarenotregardedbeingasefficientasviralvectors
and they are usually capable only of short term expression (SchmidtWolf and Schmidt
Wolf,2003).
Physicalmethodsrelyontheuseofphysicalmanipulationofthecellstogainaccessfor
the naked plasmid DNA to gain access to the inside of the cells. The simplest method
wouldbedirectinjectionofgeneticmaterialeithersystemicallyorintothetissue.Theuse
of naked DNA without any carrier molecule is also the safest method as it minimizes
factors affecting the potential risks posed by the gene transfer.However, nakedDNA is
rapidly degraded or cleared from circulation by nucleases and phagocytes, respectively,
anditmaythereforelimittheexpressionandtheefficacygreatly.Inordertoimprovethis
possibility, several physical manipulations, such as electroporation, bioballistics,
sonoporation,hydrodynamicsandmagnetofectionhavebeendeveloped(MehierHumbert
and Guy, 2005). Cell membrane penetration can be aided by the formation of transient
pores, thereby enhancing gene transfer efficacy by the controlled use of electricity




a large volume of nakedDNA solution is rapidly injected into the patient and the high
pressurecausedbytheinjectionforcesthegeneticmaterialtoenterthecells.
Chemicalmethodsofgenedeliverycanbeconsideredasanattempts tosimulateviral
carriers instead of forcing DNA to enter the cell mechanistically. The most extensively
studied and used chemical methods of gene delivery involve cationic polymers and
liposomes, which have been shown to be more efficient in transduction than physical
methods (Pichon et al., 2010, Gao et al., 2007). Cationic polymer carriers, such as
polyethylenimine (PEI), form 100 nm nanoparticles or polyplexes, when combined with
negativelychargedDNAduetoelectrostaticforces.WhenDNAiscombinedwithcationic
lipomers,suchas1,2dioleoyl3trimethylammoniumpropane(DOTAP)or1,2,dioleoylsn




Although targeted treatment is not a novel concept inmedicine, the specific targeting of
drugmoleculesdidnot,however, beginuntil the 1980s as theproductionofmonoclonal
Abs was discovered by Köhler and Milstein (Kohler and Milstein, 1975). Conventional
treatmentofGBMbyvariousmodalities isoften limiteddue to thebroadandunspecific
effects of the nontargeted drug. This is especially true in the treatment of intracranial
lesions as they are surrounded by the BBBwhich can inhibit many drugs from gaining
access to the brain. Functional drug targeting provides the possibility to confine this
limiting toxicity within the tumor where it is needed, therefore decreasing overall side
effects even in equal dosing regimens (Goodwin andMeares, 2001). Simultaneously, via
drugtargetingsimilartreatmenteffectscanbeachievedalsowithlowerdosesofthedrugs
asarelativelyhigherpercentageof thecirculatingdrugactuallyreaches the tumor.Drug
targetingcanalsobeusedtoincreasethepermeabilityofthedrugthroughtheBBBwiththe
useofvariousmolecularTrojanhorses,encapsulationsormodificationsofthedrug(Zhou
et al., 2011, Frank et al., 2011, Boado et al., 2010). In addition to longer survival and








Drug targeting can be achieved by several steps each increasing the specificity of the
treatment(Goldenbergetal.,2006).Thesimplestmeansofdrugtargetingisa‘onestep’–
method,ordirect targetingwhere thedrughasbeenconjugatedwitha targetingmoiety,
such as anAb. The drug/targetingmoiety –complex is then administered to the patient,
where the drug targets a specific cell or organ. Although themethod is not completely
accurate, it can decrease the toxicity of the treatment in other, offtarget organs of the
patient.Inanefforttoincreasetheoverallefficacyofdrugtargeting,additionalstepshave
been included into the regimen thereby creating a protocol for indirect targeting.As the






chemistry, i.e. the selection between several linkers and their characteristic properties,
aggregation and stability issues and the incapability of affecting a single moiety of the
moleculewithout inducing reactions in other similarmoieties, have increased the use of
avidinbiotin technology (Ducry and Stump, 2010). The straightforward interaction









Avidin is a tetramericglycoprotein (62.4kDa)produced in theoviductsofbirds, reptiles
andamphibians anddeposited into eggwhite accounting for 0.05%of themass (Green,




containing the biotinbinding site. The monomers further form two dimers and then
consequently adimerdimer structure leading to a tetrameric typeof avidinprotein.The
mostpredominantfeatureofavidinisitsabilitytobindbiotinatahighspecificityandhigh




essential formicrobial growth (Board and Fuller, 1974).However, avidinproduction has
been demonstrated also after mechanical tissue injury, retrovirusinduced cell
transformation and septic bacterial infection (Elo and Korpela, 1984). Avidin is highly
glycosylated, comprisingmainly ofmannose andNacetylglucosamine residues, and is a
positively chargedproteinwithahigh isoelectricpoint (pI = 10.5) (DeLange, 1970,Bruch








be purified from Streptomyces avidinii. Although streptavidin has almost identical
secondary,tertiaryandquaternarystructuresasavidin,intermstheyarenotevolutionary
related in anyway and have only 30% sequence identity and 41% sequence similarity
(Green, 1990). Streptavidin has a lower affinity for biotin (Kd = 1013 M) than avidin,
however, it isnonglycosylatedandthereforeslightlyacidic (pI=56).Thismeansthat in
comparisontoavidinithasanimprovedbiodistributionpattern,increasedserumhalflife,
tendency for renal clearance and decreased nonspecific binding to lectinlike and
negatively charged molecules, compared to avidin (Schechter et al., 1990, Rosebrough,




2001,Laitinen et al., 2006,Laitinen et al., 2007).The earlymodifications included several
chemicalvariantsofthelysinemoietiesfoundinavidinasneutrallycharged(strept)avidin
was developed. These modifications caused problems at later stages as the lysines are
commonlyusedinthepreparationofavidinconjugates(Kaplanetal.,1983,Guesdonetal.,
1979, Finn et al., 1984). However, modification of the arginine moieties overcame these
problems.Inordertofurtherdecreasetheavidininteractionswithnonspecificmolecules,
the oligosaccharides were removed either chemically or enzymatically resulting in
modifieddeglycosylatedavidins,suchasNeutrAvidin(60kDa)withavailablelysinesand
neutralchargewithpIof6.3(Bayeretal.,1986).
Novel avidin modifications include monomeric and dimeric forms of (strept)avidins
whichresolvemanyof the issuesofaggregationof tetravalent(strept)avidins(Laitinenet
al., 2001, Laitinen et al., 1999). Furthermore,mutantswith decreased or environmentally








life yet only synthetized by some bacteria, algae, yeasts,molds andplants (Mock, 1996).
Biotinisboundtospecificlysineaminogroupsofseveralcarboxylasesanddecarboxylase
enzymes where it regulates gluconeogenesis, lipogenesis, amino acid degradation and
energy transduction via the transfer of CO2 between the metabolites (Knowles, 1989,
Otsuka and Abelson, 1978, Samols et al., 1988). In addition, more than 2,000 genes are
knowntobebiotindependentinmammalsandbiotinylationofhistonesisknowntohave
aroleinDNAdamage,genesilencingandcellproliferation(Zempleni,2005).
A high content of biotin is found in egg yolk, liver and in some vegetables. Dietary
intake of biotin in the western population is estimated to be 3570 g/d (Zempleni and
Mock,1999).Biotindeficiencyisassociatedwithsymptomssuchashairloss,conjunctivitis,
dermatitis, depression, lethargy, hallucination and numbness (Zempleni et al., 2008).
However, biotin deficiency is rare as intestinal bacteria usually produce biotin in excess
amounts.
Arelativelysimpleandfastprocess,whereinbiotincanbeattachedtoanothermolecule
is calledbiotinylation.Asbiotin isa rather inert,biotinylationofothermoleculesusually






can be achieved chemically for example via nonspecific biotinylation of amineswithN
hydroxysuccinimide (Wu et al., 1992), but can be accomplished specifically by enzyme
functioninducingsitespecificbiotinylationtoachievebettermoleculestability(Stolzetal.,
1998).Biotiniscovalentlyboundtoseveralcarboxylasesthroughaspecificlysinemoietyby
an ATPdependent function of a biotin protein ligand. Initially this mechanism was







hydrophobic interactions (Figure 2). Firstbiotin is lined into thebiotinbindingpocketof
avidin monomer by hydrophobic interactions with aromatic residues found in avidin







Trp79, Trp92 and Trp108 from one streptavidin monomer and Trp120 from another
































Figure 2. The amino acid sequence of avidin and the molecular interactions in avidin-biotin 
binding. Upper row: The amino acid sequence of the avidin monomer (modified from Livnah et 
al 1983 and Pazy et al 2002). Sequence is divided into groups of ten amino acids (marked with 
_). The residues interacting with biotin are depicted in white font. The residues forming the -
sheets of avidin tertiary structure are indicated by arrows. Lower left corner: Table displaying 
each individual residues and their interaction type with biotin. Lower right corner: The molecular 
structure of biotin showing hydrophilic interactions with avidin residues. Residues with grey 
background represent amino acids that differ from the residues in streptavidin during biotin 
binding.
2.3.3.4Pretargeting
The concept of pretargeting was introduced 25 years ago by Goodwin and colleagues
(Goodwinetal.,1986a,Goodwinetal.,1986b).Theseauthorssuggestedthattumorscould










These include 2, 3, and 5step techniques and are based on the (strept)avidinbiotin –
interactions.The2stepprotocolwastestedinastudyconductedinovariancancerpatients,
where the biotinylated antifolate receptor Ab was injected intraperitoneally (i.p) to 15
patients, followed by i.p. injection of 111Inlabeled streptavidin three to five days later.





step protocol in patients with carcinoembryonic antigen (CEA) expressing tumors
(Paganelli et al., 1991). A total of 19 patients were injected intravenously (i.v) with
biotinylated antiCEA Ab, followed by unlabelled avidin injections three days later.
Unlabelledavidinwasadministered to clearnonboundAbs from theblood. In the third
step,111Inlabeledbiotinwasadministeredtothepatients.Alltumorswereexaminedwith
reasonable tumortobackground ratios. Since avidin has a much shorter halflife in the
circulationthanitsbacterialcounterpart,streptavidin(Nordlundetal.,2005b)itwasused
asaclearingagent.AvidincanrapidlybindtobiotinylatedAbswithinthecirculationand
even if left unbound, it clears rapidly through the liver and the kidneys in contrast to
streptavidin,whichhasarelativelylonghalflife inthecirculation.Duetothisandlower
nonspecific binding profile of the streptavidin, it exhibits better characteristics to bind
tumors pretargetedwith biotinylatedAb than avidin. Therefore, the 3step protocolwas
modified by replacing the second step with a sequential injection of avidin and
streptavidin. This 4step protocolwas used in an imaging studywith 30 ovarian cancer
patients (Magnani et al., 2000). In all patients, the lesions were visualized and no false
negativeresultswereobtained.Finally,a5stepprotocolwasdevisedwithanextraclearing
agent in the form of biotinylated albuminwas introduced to remove excess streptavidin
fromthecirculation(Paganellietal.,2001,Paganellietal.,1999).Patientswitheithergrade




was injected. From a total of 48 patients, the results showed a complete response in 4
patientsandapartialresponsein2patients.
Table 3. Pretargeting protocols in clinical use. 
Protocol Step Explanation 
2-step Biotinylated Ab 
(Strept)avidinylated therapeutic agent 
Accumulates into tumor 
Binds to monoclonal Ab 
3-step Bioinylated Ab 
Avidin 
Biotinylated therapeutic agent 
Accumulated into tumor 
Binds to Ab 
Binds to avidin 
4-step Biotinylated Ab 
Avidin 
Streptavidin 
Biotinylated therapeutic agent 
Accumulates into tumor 
Clears Ab from circulation 
Binds to Ab in tumors 
Binds to streptavidin 




Biotinylated therapeutic agents 
Accumulates into tumors 
Clears Ab from circulation 
Binds to Ab in tumor 
Clears streptavidin from circulation 
Binds to streptavidin in tumor 
2.3.3.5Deliveryproblemsduetobloodbrainbarrier
TheBBBisaphysicalbarrierpresentinthemicrovasculatureofthebrainwhicheffectively








dense and contains multiple tight junctions between the ECs forming a closed vessel
structure restricting the free paracellular passage of large hydrophilic molecules or
microscopicorganisms into thebrain. Second,ECsof theBBB share thebasalmembrane
withpericytes,whicharephagocytoticcellsregulatingtheBBBpermeabilityandcapillary
blood flow. Furthermore, the astrocytic foot processes, are found surrounding both
pericytes and ECs forming an additional barrier zone, glia limitans. Although various
metabolic molecules cross the BBB through active transport via specific transporter
proteins,manychemotherapeuticcompoundsarenottakeupbytheseproteins.Naturally,
as the tumorgrows,GBMwilldisruptpartof theBBB insomeareas,grantingaccess for
moleculesintothetumor(Schneideretal,2004).
Studieshave shown that only small lipophilicmolecules (< 500Da) can cross theBBB
passively by lipidmediated free diffusion and this is a requirement that excludesmore
than 98 % of all small molecules (Reith, 2007, Kirkwood and Sears, 1976). Thus vast
majorityof smallmoleculesaswell asother largerand/orhydrophilicmoleculesneed to
utilize an active transportation system,  the carriermediated transport (CMT) or the
receptormediated transport (RMT) (Pardridge, 2002b,Uenoet al., 2010).RMT transports
specificmoleculessuchasAbs,insulinortransferrinviaclathrindependentorindependent
endocytosis.Dependingonthereceptorlocationontheluminalandabluminalmembranes,
RMT can be either unidirectional, such as is the case for immunoglobulin Fc receptor
(braintoblood) and scavenger receptor (bloodtobrain), or bidirectional, such as the
transferrinreceptor(bloodtobraintoblood)(Skarlatosetal.,1995,ZhangandPardridge,
2001a,ZhangandPardridge, 2001b). InCMT, themovement ofpolarmolecules, such as
glucoseandaminoacids,acrosstheBBBareregulatedbyspecificcarrierproteins,suchas
GLUT1andLAT1, inabidirectionalmanneracrossthemembranes(Uenoetal.,2010). In
addition, the CMT also is subjected to a competition between the transportedmolecules
andsaturationofthesystem.However,dependingonthesituation,CMTcanberegarded
aspassivefacilitateddiffusionorasanactivemeansoftransportrequiringtheconsumption
of adenosine triphosphate (ATP) for energy (e.g.Na+/K+ pump). In addition toRMT and
CTM, a third transportation system exists in the BBB called the activeefflux transport
(AET);thisisanunidirectionalsystemcomprisingofseveraleffluxproteins,suchastheP
glycoproteinandorganicaniontransportingpolypeptide type2.AETmediates theactive




addition, treatment efficacy can be further increased by inhibition of AET function by
scapegoat drugs. Molecular Trojan horses are engineered fusion proteins or chimeric
peptidesconsistingofthetherapeuticdrugandthemoietyresponsibleforassistingpassage
across the BBB. The principle of the method was demonstrated in a study with double






patients. However, crossreactive antigen epitopes capable of Ab binding are generally
foundalsoinofftargettissuesandorgansandthisreducesthebenefitsoftargetedtherapy.











like domains of MSRA with avidin, thereby creating a fusion protein containing the
cytoplasmic and transmembrane domains ofMSRA fused to avidin (Lehtolainen et al.,
2002). Scavidin was shown after retroviral transduction to be expressed mainly in a
tetrameric form on cell membranes where it showed some degradation after 10 hours.








vivo.However, itwasobserved that theLDLRfusionproteinhadamorestablestructure
thanthescavengerreceptorfusionprotein.Lodavinwasnotdegradedsignificantlyafter11
hours.Althoughbothfusionproteinssharedsimilarintracellularlocalizationsbeingmostly
in the vesicular structures in early endosomes, Lodavinwas found to be localizedmore
abundantlyon the cell surface compared toScavidin, an importantproperty for targeted
therapies. Earlier studieswith Scavidin had shown nonspecific binding of the avidin to
some extent to negatively charged materials, such as lectins. In order to reduce this
unwantedproperty,threevariantsinwhichtheavidincomponentofLodavinwasmutated
were generated; nonglycosylated, acidic pI and nonglycosylated acidic pI Lodavin.
However,biotinbindingstudiesshowedthattheacidicpILodavinmutantswereinferior




its best 5 % after SFV based gene transfers. However, biotinylated HRP and transferrin
were shown to accumulate into the areaof gene transfermore efficiently than in control
animals, suggesting efficient targeting of both biotinylated small molecules and active
ligands. Although direct comparison of avidinfusion protein is not possible due to the






Figure 3. Schematic illustration of the expression of the avidin-fusion protein on the cell 






of the envelope glycoprotein gp64 (Räty et al., 2004). The produced vector displaying
avidin on the envelope, Baavi, was demonstrated to have a significantly increased







transduction efficacy and ability to be targeted into cells expressing EGF, CD46 or



















tend to have a relatively greater effect on the rapidly proliferating cancer cells than the
healthy normal cells. Therefore, the GBM is a good potential malignant candidate for




armed Abs, oncolytic viruses, antiangiogenic treatments and genetic corrections of the
underlyingmutationsofthemalignantcells.
Currently,thefoundationoftargetedtreatmentofGBMiscommonlybasedontheuseof
monoclonal Abs directed against the specific tumor antigens, such as overexpression of
EGFR. The main problem in the use of extremely specific treatments is that despite
improvingthepatientsurvivalandwellbeinganddecreasingthetoxicityofthetreatment,
themodality is toospecific tocombatan increasinglyheterogenoustumorsince thereare
constant mutations occurring within the tissues. Therefore, the use of highly specific
targeted therapies may actually, to some extent, cause the eradication of certain less
aggressivemalignant cell types or subpopulation leading to the ‘evolution’ of the tumor
tissueintoamoreaggressivehypermutatedform(CasiandNeri,2012).
2.3.5.1Suicidegenetherapy
In suicide gene therapy, an inactive nontoxic prodrug is converted into an active toxic
metabolite within the tumor due to the catalytic action of enzymes (Iwami et al., 2010).
Suicidegene therapy iswelladapted to the treatmentofGBMas the toxicmetabolitesof
prodrugsgenerallyinhibitimportantfunctionsincelldivisionandarethereforeinherently
targeted only to the dividing tumor cell. The cells in the brain parenchyma do not
proliferate. In addition,many of the toxicmetabolites are able to diffuse to neighboring
cellstherebyevokingasocalledbystandereffectthatcausetocelldeathsalsointhosecells
that does not expressing the suicide gene (Lawler et al., 2006). Themostwidely studied
suicidegene/prodrugcombinationistheHerpessimplexvirusthymidinekinase(HSVtk)
and ganciclovir (GCV) therapy (Pulkkanen and YlaHerttuala, 2005). When the i.v.
administeredGCV,ananalogueof2deoxyguanosine,reachesthecellscontainingHSVtk
after local gene transfer, GCV is phosphorylated by the HSVtk into its monophosphate
derivate. GCV is then further phosphorylated by the cellular kinases into GCV
triphosphate,thetoxicmetabolitethatinhibitstheincorporationofdGTPintoDNAduring
the Sphase of cell cycle resulting in termination of DNA elongation process and cell
proliferation (Mesnil and Yamasaki, 2000, Rubsam et al., 1998). In order to target the














The body’s natural defense against glioma or any other cancer is through activation of
immune defense against the transformed cells. However, it is known that cancer cells
actively suppress the immune system (Hussain andHeimberger, 2005). First, due to the
immunologicallypriviligednatureofthebrainasitissurroundedbytheBBB,itcontains
no or only a lownumber of natural killer cells (NK), and a very low amount ofMHC I
expression and lacks conventional lymphatic vessels (Branco et al., 2011, Vauleon et al.,
2010, Yamasaki et al., 2003). Second, tumor cells release/express several molecules with
immunosuppressiveproperties,suchastransforminggrowthfactor	(TGF	),interleukin




downregulate the activating receptors on NKs and cytotoxic Tcells. Lastly, the tumor
microenvironment harbors several immunosuppressive cell types, such as regulatory T
cellsandmyeloidderivedsuppressorcellswhichinhibitTcellsanddendriticcells(DCs),
whichagaininhibitNKs(Albesianoetal.,2010).
Thegoalof immunotherapyis toactivatethehost immunesystemandtosensitizethe
tumor for effective eradication and disease control either by adoptive or active means
(Vauleonetal.,2010). Inadoptiveimmunotherapy,theimmunecellsareactivatedexvivo
andthentransferredbackintothetumoror tumorcavityof thepatient.Forexample, the
activationof immune cells canhappenby ex vivocultivationof autologous leukocytesor
tumorinfiltrating leukocytes in the presence of high concentration of IL2 leading to
subpopulationoflymphokineactivatedkillercells(LAK)containingTcellsandNKswith
specific cytolytic properties against the tumor (Dillman et al., 2004). There have been
severalclinicalstudiesexaminingthetreatmentoftumorswithLAKs,however,thetoxicity
ofthetreatmenthasbeenrathersevereandtheefficacyvariable.OnerecentFDAapproved
adoptive immunotherapy treatment isSipuleucelTbyProvengeused in the treatmentof




acidphosphatase (Wesleyetal.,2012).  Inaddition, it isworthnoting thatAbsalonecan
elicit cell death through antibodydependent cellmediated cytotoxicity (ADCC) or
complement dependent cytotoxicity (CDC). Once bound to tumor cell antigen, the Fc
domainofanAbisavailableforNKsorcomplementprotein,dependingonthestructureof
the Ab. In ADCC, NKs become activated via the Fcdomain and then release perforins
which are poreforming proteins as well as proteolytic enzymes and chemokines that
eventually force the tumor cell to undergo apoptosis (Gartner, 2006). CDC leads to a
complementdriven apoptosis, where the Fcdomain of Ab activates a cascade of
complementproteinswhichattachthemselvestothecellmembrane.Afterattachment,they
form a membrane attack complex that promotes membrane pore formation and water
diffusion into the cell, leading to cell death (Knowles, 2005). For example, rituximab is a
commercially available chimeric Ab targeted to CD20 on the Bcell membrane and Fc
domain forbothADCCandCDC.Rituximab isused in the treatmentof severaldiseases
characterizedbyanexcessofBcells,suchaslymphomasandleukemias(Meyetal.,2012,
Schlaak et al., 2012). Another example is ipilimumab, a human antibody that binds to
cytoxic Tlymphocyteassociated antigen 4 which downregulates Tcell activation.





Active immunotherapy, or tumor vaccination therapy, consists of administration of
antigens to the patient in order to promote a tumor specific immune reaction. Antigens
fromvarioussources,suchasinactivatedtumorcells,tumorlysatescontainingproteinsor
mRNA or natural and synthetic peptides can be used alone, with adjuvants or in
combination with antigenpresenting cells (Myc et al., 2011). Although various cancer
vaccination therapies are under experimental investigation or in clinical trials, the fact




Immunoconjugates are tumorspecific Abs or Abfragments armedwith awide array of
differenthighlytoxic therapeuticagentssuchasdrugs,toxins,radioactiveligandsaswell
as prodrug converting enzymes (Casi and Neri, 2012). As the antineoplastic drugs are
associated with offtarget toxicities, the possibility of minimizing this drawback by
combinationwiththehighlyspecifictargetingabilityofamonoclonalAbisinteresting.For
example, the Abbased drug carrier, Brentuximab vedotin consists of a monomethyl








radioisotopes (radioimmunotherapy) is an interesting immunoconjugate modality as it
combines the specificity of tumorhomingAbswith thenondiscriminating cell killingof
ionizingradiation,enablingitseffectiveusealsoinsolidtumormasses(Aartsetal.,2008).
TheFDAapprovedradioimmunotherapeuticmodality,Ibritumomabtiuxetanconsistsofa
CD20 targeting chelate labelled with either 90Yttrium or 111Indium. It is used in the
treatment and imaging of Bcell nonHodgkins lymphoma (Arrichiello et al., 2012).
Antibodydirected enzymeprodrug therapy (ADEPT) is a highly targeted treatment that
combinesthespecificityofAbswiththeselectivityofprodrugtherapies(Bagshawe,2009).
The first clinical trial usingADEPTwas conducted against colorectal carcinoma.ADEPT
consistsofaAbfragmentagainstCEAconjugatedwithbacterialenzymecarboxypeptidase




oncolytic viruses (OVs). Tumor cell destruction takes place due to the lytic cycle of the
viruses.Ultimately,thereplicationendsinthelysisofthehostcellasitbecomesfilledwith
viral particles. These particles are then subsequently released into the surrounding
extracellularspaceafterwhichtheycaninfectothercellsandrepeatthecycle.Inaddition,
cellscanbedestroyedduetodirectcytotoxicityofcertainviralproteinsorbecauseofahost
immunereactiondueto immunogenicviralpresencewithin thecancercell (Wollmannet
al.,2012).OVscanalsobeengineeredtoprefertumorcellseitherbysurfacemodifications
or conditioning so that they replicate in response to tumorspecific promoters or specific
mutations, such as defective p53. For example, ONYX015 is a modified oncolytic
adenovirus that lacks theE1Bgeneencodingproteinnecessary forp53silencing forviral
replication (He et al., 2009, Opyrchal et al., 2009). Therefore, ONYX015 is incapable of






and Sindbis virus, have been evaluated in treatment of GBM with promising results
(Gridley et al., 1998, Martuza et al., 1991, Wollmann et al., 2005). In these studies, a
neurovirulent, thymidine kinasenegative mutant HSV was used in the treatment of U
87MG gliomas achieving prolonged survival in an orthotopic nude mice model.
Furthermore,   a recombinant VV was used in combination with radiotherapy in p53
deficient C6 rat glioma in athymic mice, resulting in significantly decreased tumor
progression.Finally,SINwasfoundtospecificallyeradicateU87MGcellsbothin invitro
coculturewithhumanfibroblastsandinaninvivoSCIDmicemodel.Multipleclinicaltrials
using OVs, such as HSV, reovirus, Newcastle disease virus, measles virus, vesicular
stomatitisvirusandVV,totreatGBMhavebeenconductedrecently(reviewedbyHaseley





uncontrolled cell division and dysfunctional apoptotic safety mechanisms (Ohgaki and
Kleihues, 2009), one approach to cancer therapy is to normalize these cell functions. For
example,thegrowthpromotingeffectsofEGFRoverexpressioncanbecounteredeitherby
highaffinityinhibitoryantiEGFRAbswhichcompetewiththenaturalligandorwithsmall
molecules interfering with the downstream signalling. Cetuximab, a chimeric Ab, is a
targeted inhibitorofEGFRfor the treatmentofmetastaticcolorectalcancerandheadand
neckcancer (Niyazietal., 2011).Furthermore, thereareseveral tyrosinekinase inhibitors
available thatbind to the intracellularATPdomainofEGFR, therebyeffectivelyblocking
thesignalingcascade(BerezowskaandSchlegel,2011).PhaseIandIIclinicaltrialsinGBM





express either similar signaling pathway mediators as mentioned above or functional
versions of themalignant proteins, such asmutated p53 or RB1, in order to restore the
ability lost due to the cancerous mutation in the cell (Rao and James, 2004). Several
publicationshaveshownthatbyintroducingthefunctionalproteinintothemalignantcell
expressing the mutated form of the protein, it is possible to inhibit aggressive growth
and/or activate apoptosis. For example, reduced proliferation of tumor cells has been
observed invitro upon introduction ofwild type p53 through gene transfer (Asai et al.,




by theVEGF–familyproteinsandreceptors (Belletti etal., 1979).However, severalother
stimulating and inhibiting molecules are known to take part in this tightly regulated
process(Samaranayakeetal.,2010).Inorderforatumortogrow,angiogenesisisnecessary
as diffusion of nutrients is not sufficient to satisfy the growing metabolic needs of the
tumormass.Itiscommonlythoughtthatatumorcannotgrowlargerthanasizeof23mm3
without angiogenesis (Folkman, 1971, Singh and Agarwal, 2003). GBM is a rapidly
proliferativetumorcharacterizedbyhighlyangiogenicfeatures,suchasoverexpressionof
VEGF, VEGFR and platelet derived growth factor (PDGF). In addition, many tumor
microenviromental factors can induce angiogenesis within the GBM. Under hypoxic




expression and promote angiogenesis (Samaranayake et al., 2010). Acidosis due to an
extensive Warburg effect is commonly present in cancer cells and can promote
angiogenesis.Warburgeffectisdefinedasanaerobicglycolysisfollowedpredominantlyby
lactateproduction in cytosoldespite thepresenceofoxygen thatwouldnormally lead to
formationofpuryvateinglycolysisandfollowingaerobicmetabolisminoftheKrebscycle
(KimandDang,2006).Furthermore, thenatureof theGBMvasculatureisskeweddueto




anddecrease the tumor vasculature in order to interferewith themetabolic demands of
tumor. In addition, the reduction of interstitial pressure due to decreased vascular
permeabilityenablesbetterbioavailabilityofdrugstothetumor.
Antiangiogenic treatments of GBM are already commercially available in addition to
manybeingevaluatedcurrently inclinical trials.The firstFDAapprovedantiangiogenic
therapy was bevacizumab, a humanized Ab against the VEGF for treatment of several
cancers, such as colorectal, lung, breast, kidney and GBM (Thompson et al., 2011).
Bevacizumab has a somewhat controversial status, as it has been shown to increase the
progressionfreesurvivalofpatients,yetwithoutanyradiographicalproofofitsanticancer
activity (Kreisl et al., 2009). It has been hypothesized that amajor part of bevacizumabs
efficacy would be due to simply symptomatic release by decreased edema within the
tumor.However,promisingresultshavebeenfoundinretrospectiveanalysesandinPhase
II studies suggesting bevacizumab an effective treatment for recurrent GBM (Specenier,




Photosensitizers, such as protoporphyrin IX (PpIX) and temoporfin, are chemical
compounds, which are able to absorb light and then release the stored energy as
fluorescence and a singlet oxygenmolecule (Eljamel, 2008). These compounds can have
dualfunctions;theycanbemarkersfortumorcellsduringinitialsurgeryandthentheycan
specifically kill tumor cells. The PpIX precursor is a 5aminolevulinic acid (ALA) that is
naturallysynthetized inallmitochondriaofmammaliancells fromsuccinylCoAbyALA
synthetase (Hunter and Ferreira, 2011). ALA is transported to cytoplasm and
dehydrogenated to coproporphyrinogen III and transferred back to mitochondria as
protoporphyrin III where it is further transformed into PpIX. Normally, PpIX is further
chelated with iron forming haem. However, administration of ALA bypasses the rate




inducedby lowpHandpresenceoforganicanion transporters (Novotnyetal.,2001and
Stummeretal.,2003).SincePpIXisabletoabsorblightat404nmemittingaredspectrum





2010). Since the cell killing requires the bioavailability of the photosensitizer in large
quantitiesandthespecificbandoflightdirectedtothecells,photodynamictherapycanbe
considered to be a highly targeted and specific formof cancer treatment. Several clinical




resectionofGBM,resulting in improvedsurvival inbothnewlydiagnosedandrecurrent
GBMs(Eljameletal.,2008,Pichlmeieretal.,2008).
Hyperthermia,i.e.increasedtissuetemperature,causesmanymolecularchangeswithin
the cells. The functions of several enzymes and proteins are altered causing potential
changes in theDNA, due to the impairment of repair enzyme activity, decreased active
membrane transport and destabilized membrane potential are increasing nonspecific
molecularintakeofthecell(Christophietal.,1998,CossandLinnemans,1996,Wongetal.,
1993). Alterations in various intracellular functions lead to apoptosis, if the condition is
prolonged.However, due to thepresence of severalmutations in cancer cells interfering
withvariousnormalsurvivalfunctions,tumorcellsaremoresensitivetosuddenchanges
in the temperature than healthy cells (Kobayashi, 2011). In hyperthermal therapy, tissue
temperature is increased to 4142 °C,which is enough to induce the cell death of tumor
cells,yetsparingmostofthehealthycells.Althoughtheincreaseintissuetemperaturecan
be achieved relatively easily by severalmethods, such as ultrasound ormicrowaves, the
problem of hyperthermal treatment is to restrict the heat elevation specifically to tumor
tissueandattainahomogenoustemperatureinthelesionsoastoefficientlykillalltumor





bypropertiesof theparticles, suchas sizeandmagnetizationstrength,and this createsa
uniform thermal change in the tumor tissues due to heat transfer. Numerous studies
concerninghyperthermaltherapyhaveshownefficacyinvitro,invivoandinclinicaltrials.
In vitro studies have shownhyperthermal therapy to cause, in addition to cell death, an
increaseinimmunogenicityagainstthetumortissuesbyactivatingtheheatshockprotein
70(Itoetal.,2003).ImmunogenicitycausedbyamplificationofCD8+andCD4+Tcellsdue
to hyperthermal treatment was demonstrated in vivo in a study where mice received
treatmentonlytoa tumormassonthe left flank,yetshowedregressionof tumoralsoon
therightflank(Yanaseetal.,1998).Hyperthermiahasalsobeenshowntosensitizetumors








Nanomedicine is a field of science where nanotechnology is exploited in medicine.
Nanotechnologyreferstotheuseofobjectshavingatleastoneofthedimensionsranging
from 1 to 1000 nm. The origins of nanomedicine can be found in the 1950s and 1960s
(Duncan,2003),however,onlyrecentlyhasitbeenstudiedvigorously.Nanoscalematerials
have unique physical, chemical and optical properties that are not present in
macromolecules and these can be harnessed in several treatment, imaging or research
protocols (Blanco et al., 2011, Davis et al., 2008). Due to these properties, nanoparticles




treatment, as the reticuloendothelial system (RES) in particular the macrophage cells,







between the endothelial cells (normal blood vessels have gaps less than 2 nm).
Furthermore, the deficient lymphatic drainage within the tumors results in the
accumulationofNPswithinthetumor(Maeda,2001,MatsumuraandMaeda,1986,Peeret
al., 2007). In addition, high surfacetovolume ratio means that these particles can have
relativelyhigh loadsof functional groupsordrugmolecules attachedon their surface in
comparison to other macrosized carrier systems, giving rise to multipurpose NPs.
Furthermore, since many chemotherapeutic drugs are insoluble in aqueous solutions
(Guven et al., 2012), preparation of stable formulations of the drugs is very difficult.
Various NP types have inner hydrophobic compartments that can engulf the insoluble
drugs with ease even in aqueous solutions (Allen and Cullis, 2004). In addition, when
confinedintoaNP,thechemotherapeuticdrugisalsoshieldedfromoutsideforcesthereby




from phospholipids or polymers, whereas the inorganic NPs are of metallic or
semiconductororigins.ThedifferentNPstructuresareshowninFigure4.
LiposomesandmicellesareNPs,whichrangefrom2.5to400nmindiameter,andare
composedof lipids. Thesehavebeen themostwidelyused and studiednanoparticles in
cancer therapy.  They are synthetic or natural amphiphilic phospholipids with a
hydrophilicheadandhydrophobic longchaintails thatselfassemble inaqueoussolution
intosphericalstructureswithlipidmono(micelles)orbilayers(liposomes)(Malametal.,
2009,Torchilin,2007).Inliposomes,thehydrophobictailsspontaneouslyformthemiddle
compartment of the liposome leaving an aqueous inner compartment. The micelles are
monolayered and have the hydrophobic inner compartment in aqueous solution.




generallywell toleratedandmaygainentry tocellsmoreeasily thannanoparticlesmade
fromothermaterialsduetothefactthattheypossesssimilaritieswiththecellmembranes.
NPscanalsobemadeofsyntheticandnaturalpolymers,generallyfrombiodegradable
and biocompatible polymers (Duncan, 2003, Park, 1995). Depending on the polymer
properties,polymericmicellesorpolyelectrolytecomplexmicellescanbeproduced(Golan
and Talmon, 2012, Kataoka et al., 2001). Polymeric micelles are similar to lipidbased






compartment capableof transportationof bioactivemolecules, such aspeptides,proteins
and nucleic acids (Ding et al., 2011,Hartig et al., 2007, Lu et al., 2012).Another type of
polymer NPs is the dendrimers, which are repetitively branched molecules (Lee et al.,
2005). They are commonly synthesized from poly(amidoamine) (PAMAM). Dendrimers
form treelike structures that usually are monodisperse, symmetrical and spherical
compounds due to the steric interactions between individual molecules. During the
productionofpolymericNPs, the therapeuticdrugormolecule canbe entrappedwithin
the polymer solution, conjugated into various functional groups, or capturedwithin the









Fe2O3). Generally, metallic NPs have a coreshell structure as they are coated with
polysaccharides,polymersorliposomesinordertoconferbetterbiocompatibility,aqueous
solubilityandaccess to functionalgroups.Due to thequantummechanisticpropertiesof





Yguerabide, 1998b). However, the spherical shape of noble metal NPs is not the most
optimalforSPRandthereforea‘nanocube’formmaybemorebeneficial(Sannomiyaetal.,
2009).Inaddition,theSPReffectalsorepresentsameansforphotothermaltherapyasthe




Novel coated iron oxide NPs may also serve as multipurpose modalities. Thus, single
nanoparticlemaybeusedforrealtimeimaging,ascarrierforachemotherapeuticdrugand
asamediatorforhyperthermictreatment.Inhyperthermictreatment,theNPisexposedto
alternating magnetic field inducing heat dissipation from the magnetic NPs into the
surroundingtissues(Dasetal.,2009,Jordanetal.,1997,Jordanetal.,1996).
NPs can also be produced of semiconductormaterials, such as technetium, cadmium





the nanoparticle which is covered with a zinc sulfide shell to achieve improved optical
characteristics(ReschGengeretal.,2008,SmithandNie,2010).QDsareusedcommonlyas
fluorescentmarkersastheyhavemultipleadvantagesoverconventionalorganicdyes.For
example, theyhaveabroadabsorption rangeand they canbeexcited far away from the
emission peak, thereby decreasing background scattering and enabling multiple QD
excitationandrecognitionwithasinglelightsource.Inaddition,thefluorescentemission
of QDs are tunable via size and material selection to 450 – 850 nm and they exhibit
exceptionallynarrowpeaksnear to theGaussian centre allowingmoreprecise emissions
without there being overlapping fluorescence originating from differentwavelengths. In
addition,thestabilityandyieldofQDfluorescenceisfargreaterthancanbeobtainedwith








Figure 4. The nanometre scale and structure of different types of nanoparticles. Upper row: 
Nanometre scale ranging from 1 nm to 1,000,000 nm. Middle row: General structure of 
different nanoparticles. Lower row: A detailed view of nanoparticle structure and compartments.
2.3.6.2Surfacemodificationofnanoparticles
SurfacemodificationsofNPsopenawidevarietyofnewpossibilities,suchasshieldingor
targeting of them. As therapeutical NPs are foreign material within the body, they are
subjectedtoconstantattackbytheimmunesystem.Thisleadstoadecreasedhalflifeofthe
NPs and potential treatment failure. Therefore, one of the most common surface
modifications is aprocess called ‘PEGylation’ that refers to the covalent incorporation of
polyethyleneglycol(PEG)ontotheparticlesurface(Klibanovetal.,1991,Moketal.,2009).
PEG forms a protective hydrophilic layer around theNP, thereby effectively shielding it
fromopsonizationandeliminationbymacrophages.AlthoughtheNPsaccumulateintothe
tumor site by apassiveEPR effect (Matsumura andMaeda, 1986), the addition of active
targetingmolecules, ligands that specifically bind tomoieties overexpressed or uniquely
presentonthetumorcellmembrane,intotheNPsurfacecanfurtherincreasethespecificity




tissue. Some, but not all, targeting molecules can induce endocytosis at the target site.
Therefore, highly cationic cellpenetrating peptides, such as protamine, or aminated
syntheticpolymers,suchasPEIcanbeusedtoallowtheNPstogainentrywithinthecells.





2.4 ANIMAL MODELS FOR MALIGNANT GLIOMA RESEARCH 
Althoughmanyexperiments incancerresearchcanbedone invitro, there iscurrentlyno
approved alternative disease model in vitro that could replace the data obtained from
animals.Ascancer isamultigeneticdisease,apreciseand robust invivocancermodel is
essential inmostof the studies.However,noneof the currently available animalmodels
fully reflect the clinical setting encountered inHGgliomas of humanpatients. There are
variousgeneticdifferencesbetweenmolecularpathwaysinanimalsmodels,whichmaynot
matchthepathwaysfoundinhumangliomagenesis(DaiandHolland,2001).
In a GBMmodel (Barth and Kaur, 2009), the cells should be derived from glial cells,
which would grow in vitro as continuous cell lines and can establish a tumor upon
transplantation.Invivotumorgrowthshouldbepredictableandreproducibleandshowthe
characteristicfeaturesofGBM,suchasneovascularization,alterationofBBB,invasiveness,
lackof capsulationand the correct intracerebral location.Furthermore, themodel should
allowsufficientsurvival timeof thehostanimals topermitadequateperiods for therapy.
Especially in therapeutic studies, theoptimalGBManimalmodel shouldbeonlyweakly
immunogenic and tumor response to treatments should be predictive of the response in
humanpatients.
The choice of a GBM model for research depends on many different considerations
(BarthandKaur,2009).Generally,thelargertheanimalusedinamodel,themoreprecise
willbethestereotacticimplantation.Furthermore,betterlocalizationofthetumorscanbe





the regional ethical committee permission and it should give an answer to the question





cell line in vivo, as tumors can be established in athymic, so called ‘nudemice’, with a
FOXN1mutationordeletion.TheFOXN1mutationinterfereswiththedevelopmentofthe
thymus, resulting in a lack or significantly lower number of Tcells in nude mice
(Mecklenburgetal.,2005).Alternatively,severecombinedimmunodeficiency(SCID)mice
thathavespontaneousmutationinthePrkdcgeneinvolvedinthematurationofTandB
cellsmaybeusedashosts forhumanxenotransplanted tumorcells (Schuleretal., 1986).
Furthermore,aNODSCIDmouseisavailablethatisacrossbreedbetweentheSCIDmouse
and a NODmouse (nonobese diabetic); this strain has a significantly impaired innate
immune system (e.g. lack of the complement system and lower number of NK cells)
(Prochazkaetal.,1992).Onerecentlyintroducedimmunocompromisedmousemodelisthe
NOGmouse, a crossbreed of NODSCID and IL2Rgamma knockout mouse (Ito et al.,
2002).InadditiontoNODSCIDmice,theNOGmiceshowdysfunctionsindendriticcells
and macrophages. However, human glioma xenograft models are not invasive when
propagatedinvivoandtheymayenduplosingtheirkeygeneticalterations.
Althoughthesexenografttumormodelsharborthepossibilityofstudyingactualhuman
gliomas invivo, theyare immunodeficient, lessaggressiveandrelativelynoninvasive. In
this regards, syngeneic mouse gliomamodels, such as GL26, GL261 or 4C8may offer
some advantages (Candolfi et al., 2007). Some experiments, such as immunotherapy,
require the use of syngeneic models in order to obtain accurate data. In addition, the





disadvantage of syngeneicmodels is the necessity to use species/breed specific cell lines




Germline modifications of mice strains inducing either gainof or lossoffunctions in
tumorigenesis pathways, such as p53, IK4a/ARF, PTEN or EGFR, can create transgenic
mouse strains characterized by humanlike gliomagenesis (Politi and Pao, 2011). These
models are increasingly used in gliomagenesis studies, and their slow growth rate






xenograftsmodeldoesexist (Rowettnuderat) (Miuraetal.,2008),most ratGBMmodels
usedincancerresearcharesyngeneic.ThereareeightcommonlyusedratGBMmodels;C6,
9L,T9,F98,RG2,RT2,CNS1andBT4C.
C6 tumors were first derived from Wistar rats after repeated administration of





rats after exposure to MNU. After propagation in Fischer 344 rats, they are the most
commonly used syngeneic rat gliomamodels today (Benda et al., 1971,Denlinger et al.,
1975). The 9L and the T9 models are quite similar to the C6 model, although gene
expression pattern is not as close to human patients. Exposure of Fischer 344 rats to
ethylnitrosourea (ENU) during gestation gave rise to the highly invasive RG2 and F98
tumorcelllinesintheparentsandoffsprings,respectively(Koetal.,1980,Weizsackeretal.,
1982). Both F98 and RG2 models are low or nonimmunogenic when propagated into
Fischer 344 rats, respectively (Mathieu et al., 2007, Oshiro et al., 2001). Inoculation of
neonatal Fischer 344 rats with avian sarcoma virus gave rise to the RT2 anaplastic




which receiveda single transplacentaladministrationofENU(Laerumetal., 1977).Cells
werepropagatedandculturedinvitrofor200days,afterwhichtheybecometumorigenic.
The tumors in the BT4C/BDIX syngeneic rat malignant glioma model are hypercellular
multipolar glialike and flattened with the occasional occurrence of giant cells with
pleomorphic nuclei. Tumors showmitotic activity, necrosis and irregular, dilated blood
vessels as well as neovascularization (Stuhr et al., 2007). Although, there are not many
studiesconcerningthebasicbiologyofBT4Ccells,theyareknowntoexpressVEGF,tissue
and urokinase plasminogen activators and also they display increased mean vascular
densityintheproliferatingborderareasofthetumor(Sandströmetal.1999andSandmair
et al. 2000).Also, immunohistochemistryhas revealed thatBT4C ispositive for s100 and
GFAP. Figure 5 shows the survival and tumor growth of the BT4C/BDIX syngeneic,
orthotopic,malignantratgliomamodel.Themodelhasameansurvivalof36.5daysafter






Figure 5. The characteristics of BT4C rat glioma model as shown by two separate studies. 
Upper: The Kaplan-Meier survival graph of the BT4C rat malignant glioma model without 
treatment. Lower: The progression of the tumor as seen on weekly MRI monitoring. White 
arrows point to the tumor lesion.
2.4.3Othergliomamodels
Thereisnooriginalgliomamodelinrabbits.However,theVX2cellline,whichisarabbit
carcinoma cell line, can display the characteristics of malignant brain tumors once
propagated in therabbitbrain.Lesionsarehighlyproliferative,angiogenicandsimilar to




Mantel, 1971, Stoica et al., 2004). This ismost common in bradycephalic breeds, such as
Bostonterriersorboxers,inwhich4045%oftumorsoftheCNSarediagnosedasgliomas
(Page et al., 1991). Spontaneous GBM of dog exhibits pseudopalisading necrosis and
endothelialproliferationcloselyresemblinghumanGBManditbearssimilaritiesalsoinits
pattern of invasion.  The larger size of dogs also allows more precise operations and
assessment of drug dosing and toxicity than can be done in rodents making the
spontaneous GBMmodel of dog appropriate middlestage model for preclinical testing
before actualphase I studies.However, the spontaneousnature and the costprevent the
moreextenteduseofthismodelincancerresearch.









A relatively novelmethod of creating a humanlike glioma in any animalmodel is to
harness the molecular pathways of gliomagenesis. Thus, injection of viral vectors
expressingoncogenicfactors,suchasHRasorAKT,intobrainshavebeenshowntoinduce
tumorswithhighinvasivenessinmice(Marumotoetal.,2009)
2.5 ETHICAL ASPECTS OF GENE THERAPY 
Gene therapy is regulated in the Europe by the Bioethical Directive (Council of Europe
1998) that allows the preventative, diagnostic and therapeutic use of gene therapy in
somatic cells in the treatment of lifethreatening diseases for which there is no efficient
treatment(Vapalahtietal.,1997,YläHerttuala,2009).Genetherapyinvolvingthegermline
cells is strictly forbidden. Furthermore, the use of genetically modified organisms is
regulated by several Directives in the EU (Directives 2001/18/EC and 2009/41/EC). In
Finland, legislation includes Gene Technology Act (377/1995 and 928/2004) that is
supervisedbytheBoardofGeneTechnologyinconjunctionwithMinistryofSocialAffairs
andHealth.TheGeneTechnologyActpromotesethicallyacceptablewaysforthesafeuse
anddevelopment of gene technology andGMOs toprotect humanandanimalhealth as
wellastheenvironment.
Theway of proceeding to clinical trials in EU countries entails the compilation of an
investigationalmedicinalproductdossierthatmustbeevaluatedandapprovedbynational
agenciesandethicalcommittees(Goninetal.,2006).Thisdossiermustcontaintheprotocol






production andGoodClinicalPractice in the clinical trials. In addition,patientswhoare
participating in theclinical trialsmustbevoluntaryandtheymustbemadeawareof the
risksandprocedures involved.Asignedconsent form fromeachpatient, acknowledging







































































































































Table 4. Methods used in the original publications I - III 
Method Description Original publication 
FACS  Total expression of avidin-fusion protein I 
 Surface expression of avidin-fusion protein I 
 Quantum Dot ligand binding assay I 
HPLC Determination of nanoparticle drug content III 
 Determination of nanoparticle biotin-affinity III 
Immunohistochemistry Anti-avidin staining I, II 
 Anti CD8 staining II 
 Anti CD68 staining II 
 Anti-transferrin staining I, II 
 Direct DAB staining I, II 
In vitro Antibody response I 
 Drug release rate of the nanoparticles III 
 Neutralizing assay I 
 Targeted treatment: 3-step method III 
 Targeted treatment: Avidin-fusion protein I 
 Viral vector toxicity I 
In vivo Gene transfer: Intracranial method I, II 
 Gene transfer: Intravenous method I 
 Inoculation of tumor cells: Intracranial I, II 
 Inoculation of tumor cells: Subcutaneous II 
 Microinjection for generation of transgenic 
mouse strain 
II 
 MRI II 
 Serum collection  I 
 SPECT II 
 Targeted radiotherapy II 
Interfacial deposition solvent 
displacement 
Preparation of the nanoparticles III 
Light scattering Determination of nanoparticle size and 
distribution, zeta potential and biotin binding 
affinity 
III 
Matlab MRI data analysis II 
Nanoparticle polymer analysis Molecular weights by size exclusion 
chromatography 
III 
 Polymer structure confirmation by 1H NMR III 
 Polymer temperature behavior by differential 
scanning calorimetry 
III 
Polymer synthesis Melt polymerization: PLA-PEG III 
 Solution polymerization: bPEG-PLA III 
Statistical analysis Kaplan-Meier using Mantel-Cox log rank II 
 Kruskal-Wallis with Dunn’s multiple post hoc I 
 Non-parametric Kruskal-Wallis III 
 One-way analysis of variance I 




Transmission electron microsopy Nanoparticle morphology III 
Titer determination Viral particle titers by p24 ELISA and RT-qPCR I 
 Functional titers by FACS and qPCR I 
Vector production Cloning of 3rd generation lentiviral vector 
containing avidin-fusion protein construct 
under CAG promoter 
I 
 Concentration of the viral batch by 
ultracentrifugation 
I 
 Sequencing for cloning verification I 
 Replication competent lentivirus assay I 









Table 5. Cell lines used in the original publications I – III. Lentiviruses were produced in the 
293T cell line expressing T-antigen for plasmid episomal replication, other cell lines were used 
in both in vitro and in vivo experiments. 
Cell line Reference Species Type Original publication 
293T ATCC: CRL-11268 Human Embryonic kidney I 
BT4C Laerum et al 1977, Sandmair et al. 2000 
Rat 
GBM I, II, III 
HeLa ATCC: CCL-2 Human Adenocarcinoma I 
HepG2 ATCC: HB-8065 Human Hepatocellular carcinoma I 
U87-MG ATCC: HTB-14 Human GBM I 
U118-MG ATC: HTB-15 Human GBM II 
4.3 VIRAL VECTORS 
TheviralvectorsusedintheOriginalPublicationsIIIIareshownintable6.




transgene Vector Construct Original publication 
GFP hPGK-GFP Lenti virus Green fluorescent protein I 
Lodavin CAG Lenti virus Avidin-LDLR –fusionprotein I, II 




4.4 EXPERIMENTAL ANIMALS 
TheexperimentalanimalsusedintheOriginalPublicationsIIIIareshownintable7.
Table 7. Animals used in the original publications. 
Model Type Species Name Producer
Original
publication 
Intracranial Syngeneic Rat BDIX Charles Rivers, France I, II 
Subcutaneous Immunocompromised Mouse Balb/c nude NLAC II 
Transgenic GMO Mouse C57BL x CD1 NLAC II 
4.5 PHARMACEUTICAL PRODUCTS 
ThepharmaceuticalproductisusedintheOriginalPublicationsIIIIareshownintable8.
Table 8. Pharmaceutical products used in the original publications. 
Tradename Generic name Type
Original
publication 
Domitor Medetomidine hydrochloride Sedative and analgesic I 
Dormicum Midazolam maleate Anaesthetic I, II 
Hypnorm Fentanyl/Fluanisone Anaesthetic I, II 
Ketalar Ketamine hydrochloride Anaesthetic I 
Taxol Paclitaxel Chemotherapeutic III 
4.6 ANTIBODIES AND LIGANDS 
TheantibodiesandligandsusedintheOriginalPublicationsIIIIareshownintable9.
Table 9. Antibodies and ligands used in the original publications I – III. 
 Antibody Type Manufacturer Original publication 
Goat anti-avidin Primary Vector Laboratories I, II 
Anti-Flk1 Primary Viite Kataoka 1997 II 
Mouse anti-rat CD8 Primary Abd Serotec II 
Mouse anti-rat CD68 Primary AbD Serotec II 
Goat anti-rat Secondary Vector Laboratories I, II 
Horse anti-mouse Secondary Vector Laboratories I, II 
Rabbit anti-goat Secondary Vector Laboratories II 
DTPA ans DOTA Ligand University of Kuopio II 


















5.1 AVIDIN FUSION PROTEIN EXPRESSING LENTIVIRUS FOR TARGETED 
THERAPY (I) 
Thisstudyevaluatedafusionproteintobeusedfortargetedtherapyofcancer.Thefusion
protein consists of the endocytotic LDLR and an avidin moiety, expressed on the
membrane of the transduced cells capable of capturing biotinylatedmolecules from the
surrounding extracellular space. After interacting with the avidinfusion protein, the
molecules are endocytosed into the host cell by the LDLR endocytotic properties, after






LVs are less immunogenic thanmost other vectors and therefore should have a safer
profile than SFV (Frolov et al., 1996, Rheme et al., 2005). In addition, as lentiviruses are
integratingvectors, it ispossible that theavidinfusionprotein couldbeexpressed in the
tumorforalongtime.Still,byhavingtwodifferentviralvectors(i.e.SFVandlentivirus)for
theexpressionoftheavidinfusionprotein,onecouldconceivablyadministerthevirusesin
sequence. This could be beneficial in case the immune response from the patient had
renderedthefirstvectorusedasnonfunctional.
5.1.1Titeringofthelentivirusvector
The LDLRavidin fusion protein encoding gene was cloned into a thirdgeneration self
inactivating LV transfer plasmid and this was confirmed by sequencing before calcium
phosphate transfection in 293T cells (desribed by Follenzi and Naldini, 2002). Lentiviral
batcheswerealsotestedfortheabsenceofreplicationcompetentlentivirusesandfoundto
be negative.Viral batcheswere titered by four differentmethods (Table 10 andOriginal
publication I, table I); physical titering by p24 enzymelinked immunosorbent assay
(ELISA), viral RNA titering, functional titering by antiavidin flow cytometry and the
quantificationsofvectorDNApresentintransducedcells.
Thep24capsidproteinoflentiviralvectorwasmeasuredbyp24ELISAtoquantifythe
totalparticlenumberof aviralbatch.AsaHIVcoreparticle is composedof 2000 capsid
proteins, itcanbeestimatedthat1pgofp24represents12,500capsidparticles (Farsonet
al., 2001). These values were then used to form the physical titer of viral particles per
millilitre(VP/ml).RTPCRwasanotherphysicaltiteringmethodusedtoquantifytheviral
RNA copy number of the vector. The physical titers of the vector batches ranged from
8.1x1011 to 2.5x1012 (p24) and from 6.5x108 to 1.1x109 (RNA titer) VP/ml. However, it is
commonly known that both p24ELISA and RTPCR do not estimate the titers correctly
(Geraertsetal.,2006).Muchoftheproducedviralcapsidparticlesarefoundinfree,non
particleassociatedformsduetooverexpressionofGAGin293Tcells.Theymayalsoform
defective viral particles that do not have the viral genome inside (Geraerts et al., 2006).
Although,physicaltiteringisnotconsideredtobeexactduetoerrorsinthequantification
assays and the dependency of functional titers in vector construct and cell types
transduced, the physical titer is known to correlate strongly with the functional titer.
Therefore,byusingaconversionfactorobtainedbydividingGFPexpressingcontrolvirus
fluorescenceactivated cellsorting (FACS) titer by its p24 titer, it is possible to






To precisely analyze the actual functional titers of the viral batches, two separate cell
lines, a human malignant glioma U87 MG and rat malignant glioma BT4C, were
transducedwithvariousdilutionsofviralpreparationsandtheavidinpositivecellswere
measured by flow cytometry. The functional titers were also verified by measuring the
amountoftheintegratedvectorDNAfromthetransducedU87MGcells.Functionaltiters
were shown to be from 1.0x107 to 1.5x107 TU/ml (U87MG) and from 1.7x107 to 5.2x107
TU/ml (BT4C)whenmeasuredby flow cytometry.DNA titering of the integrated vector
yieldedafunctionaltiterof1.2x108TU/ml.

Table 10. Average viral particle and functional titers of the avidin fusion protein expressing 
lentiviruses as measured by p24 ELISA, RT-PCR, FACS, and qPCR.  
Type Viral particles (vp/ml) Functional viruses (TU/ml) 
Titer p24 RNA p24 U87MG BT4C DNA 
Method ELISA RT-PCR Estimated FACS FACS qPCR 
Batches 4 4 4 3 4 1 
Avr ± Stdev 
1.58 ± 0.7 
x1012 
7.90 ± 3.06 
x108 
2.70 ± 1.04 
x109 
1.25 ± 0.21 
x107 




       
 by p24 ELISA titering 580 126,200 45,100 13,150 
vp : TU -ratio      
 by viral RNA RT-PCR titering 0.29 60 25 7 






DNA (Sastry et al., 2002). In addition, the lentiviral vector seems to function more
efficientlyintherattissuesthaninhumantissuesasthefunctionaltiterwasfoundtobeup
to 5fold higher in the BT4C cell line. In addition, the avidinfusion protein vectors had
slightly lowertiters thanaveragecontrolvectorspointingtoapossiblecytotoxicityof the
vectorconstructorbiasintheassays.Formoreaccuratetitering,theadditionofGFPinto
theviralconstructwouldbeadvisableinordertoachievesimplisticfunctionaltiteringvia





avidin in order to evaluate the surface and total expression of the avidinfusion protein,
respectively. In addition, a mean fluorescent index (MFI) was calculated (percentage of
positivecellsmultipliedbymeanfluorescence)andthecellswereanalyzedvisuallyunder
fluorescentmicroscopy.Thestainingsrevealedthatthesurfaceexpressionrepresentabout
50 % of total expression. Interestingly however, according to the MFI, the cell surface












readministration of quantum dots. The results are in line with the biology of LDLR
endocytotic membrane recycling and point to the feasibility of ligand readministration
already1hourafterinitialdose,althoughtheefficacyincreasesprogressivelyclosertothe
initialbindingefficacyastimepasses(HaoandMaxfield,2000).
Lentiviral vectors integrate into host genome achieving, a stable and longterm
expressionoftransgenes(Naldinietal.,1996).Thedurationoftheexpressionwasfollowed
forover30days inU87MGandBT4Ccell lines. Inaddition,a fluorescentactivatedcell
sortingtechniquewasusedtofurtherselecthighexpressionsubpopulationofcells.Inboth
cell lines, the initialexpressionof90100%wasdecreasedandstabilizedat2030%after
twoweekswhereasthesortedpositivecellsstabilizedalreadyat55%(Originalpublication













glioma cell line BT4C, the human cervical cancer cell line (HeLa) and in the lentiviral
productioncell line,humanembryonickidney293T.Viable cellsweremeasuredby their
mitochondrialactivityusingacellproliferationassay.The lentiviralvectordidnotevoke
changes in any of the cell lines in the proliferation rate of the cells at clinically relevant
multipliciesofinfections(MOI)asonlyafterMOI50didthecellviabilitystarttodecrease.






with earlier studieswhereGFP has been shown to be toxic to cells (Liu et al., 1999). To
summarize, the lentiviralvectoror theexpressionof theavidinfusionproteinon thecell
membrane does not affect the viability of the cells in settings achievable after local
transductionsinvivo.
The avidinfusion proteinmediated targeted therapywas studied in BT4C cells using
biotinylatedandnonbiotinylatedpoly(lactic acid)nanoparticles (bPLANPandPLANP)
filled with the chemotherapeutic agent, paclitaxel.  Paclitaxel stabilizes microtubules
therebyinhibitingtheformationofthemitoticspindleduringmitosisthuspreventingcell
division.CellviabilityaftertargetedtreatmentofthetransducedcellswithbPLANPswas
less than 10 % whereas nonbiotinylated PLANPs resulted in up to 32 % viability.
Paclitaxeltreatmentbyitselfkilledapproximately6070%ofthecells.However,itseemed
that the PLANPs in these experimental settingswere being taken into to all cells quite
efficiently despite the targeting. This may be due to cellular pinocytosis or binding to
multivitamin receptors on the cell surface, and thismaymask the actual efficacy of the









the BT4C gliomamodel in BDIX rats injected intratumorallywith a total of 30 l of the
vector and sacrificed five days after gene transfer for immunohistochemical analysis
(Originalpublication I,Figure7AC). Inaddition, the immuneresponsewasanalyzedby














at the 3 week timepoint. Neutralizing assay was performed on BT4C cells (Original
publicationI,Figure5).Dilutionswith1 0.25%(1:100–1:500)ofserumneutralizedthe





virussuggests thatanyreadministrationof thetreatmentwouldlikely tobe inefficient if
thesamepseudotypeweretobeused.Accordingly,theserumfromthecontrolanimalsdid
neutralizethelentiviralvectoronlytotheslightestextent,suggestingthatthiswasaminor
complementdriven immunity.Asvectorneutralizationrepresentsaconcern for repeated
treatment,itisalsoknownthatavidincaninduceAbformationinvivo(Granaetal.,2002,
Hytonenetal.,2003). Inorder tofurtherstudywhetherthe immuneresponseagainst the
transgenewouldimpairthereadministrationofbiotinylatedligands,avidinAbswerethen
analyzed from the serum sampleswithELISA (Original publication I, Figure 4A andB).
The route of administration had no significant effect on the avidin Ab titers, although
interestingly the intracranial administration route showed slightly higher titers. This can
potentially be explained by more rapid neutralization of the vector in the circulation
compared to brain (Ogbomo et al., 2011, Vauleon et al., 2010, Yamasaki et al., 2003).As
expected, the latter timepoint had higher Ab titers, although elevatation did not reach
statisticallysignificantdifferences.Readministrationofthevectorhadnosignificanteffect
onthetransgeneAbtiters,asthevectorcouldhavebeeneffectivelyneutralizedasshown
earlier intheneutralizationassay.Inaddition, itwasnotedthat theavidinAbcontaining
serumsamplesinhibitedtheligandbindinginvitrobyonlyupto50%butwerenotableto
completelyinhibittheligandbinding(OriginalpublicationI,Figure4C).Readministration
of the biotinylated treatment molecule but not the same vector would therefore still be
effective,althoughtoalesserextentthanintheinitialadministration.
Inthisstudy,alentiviralvectorcontainingavidinfusionproteinwasproducedinhigh





drugs leading to increased cytotoxicity in vitro. Furthermore, in vivo experiments found
evidence for induction of immune responses against both the vector and avidinfusion
protein,slightlyhinderingtheuseofthesystem.However,avidinfusionproteinretained
itsbiotinbinding capacitydespite the immune response. In conclusion, theavidinfusion
proteincanbeusedasmediatorofthetwosteppretargetedcancergenetherapy.
5.2 IN VIVO APPLICATIONS OF THE AVIDIN EXPRESSING FUSION 
PROTEIN (II) 
AsGBMgrows,thetumorinvadestissueinahighlydiffusedelineatedpatternpassinginto
the surroundingbrainparenchymamakingvirtually impossible the complete removal of
the cancerous tissue (Louis et al., 2007). In addition, often tumors can be defined as
completelyorpartlyinoperableduetotheirlocationwithinanatomicalregionsofthebrain.
Therefore, the surgical intervention, can only be considered palliative, necessitating
additionalchemoorradiotherapy.However,asGBMishighlyheterogenous,someofthe






ofhighlyspecificcancer therapies.First, theuseof theavidinfusionproteincanassurea
universal, nondiscriminating targeted treatment that tumorspecific but not confined to
specifictumorcellsubpopulations.Second,theprotocolofavidinfusionproteintreatment
is straightforward, decreasing the number of steps to achieve functional targeting of the
treatment,thusreducingthetimethepatienthastobehospitalized.
Thus, it was decided to continue the studies which initially characterized the avidin
fusionproteinexpressedbytheSFV.Itscapabilityofbindingseveralbiotinylatedligandsin
vivo after systemic administration from the circulation and interstitial space was
demonstrated.Furthermore, itspotential formultifunctionaluse, i.e.use inboth imaging
andtreatmentpurposesoftheGBM,wasshown.
5.2.1Invivoexpressionandbiotinbindingoftheavidinfusionprotein
The avidinfusion protein was shown to be expressed and able to bind biotinylated
molecules giving positive results with several immunohistochemical stainings. First, the
expressionoftheavidinfusionproteinwasshownbyantiavidinstaininginratmalignant





two separate animalmodels; the subcutaneous nudemice and the orthotopic rat glioma
model.NudemicebearingU118MGhumangliomatumorsintheflankwereadministered
biotinylated horserahish peroxidase (bHRP) intravenously after intratumoral SFV
injections. Direct DABstaining revealed the accumulation of bHRP around the injection
area(OriginalpublicationII,Figure3Cand1D).TheconcentrationofbHRPintothetumor
demonstrated the expression of the avidinfusion protein in humanderived tissues and
proved the biotin binding capacity of the avidinfusion protein after systemic
administration of biotinylated ligands. The avidinfusion protein was shown to be
functionalinthenativecompartmentofgliomabehindtheBBB,whichwasinlinewithan














The accumulation of the biotinylated ligands into the tumors expressing avidinfusion
proteinwasdemonstratedbySPECTandMRI. In theSPECTstudy, abiotinylated linear
peptide chelate, diethylene triamine pentaacetic acid (DTPA), was labeled with 99m
Technetium (99MTc), a gamma radiating radioactive tracer (Paganelli et al., 1999). The
orthotopic rat glioma model was used and the biotinylated ligand was administered
intravenously. SPECT imaging after the intravenous injections revealed a rapid
accumulation of the bDTPA99mTc within the tumor area that was retained even after
sacrifice and perfusion of the animals (Original publication II, Figure 4). This suggests
either a high affinity binding or an intracellular localization of the bDTPA99mTc further
supporting the potential in vivo applications of the avidinfusion protein.Moreover, the
biotinylatedradiotracerwasmainlyseen in thoseareaof thebrain,withexceptionof the
thyroidthatareknowntotakeup99mTc(Bertholetal.,2003).Thissuggestshighlyspecific
targetingmethod.
Another imaging studywasdone in a transgenicmousemodel expressing the avidin
fusion protein under endothelial specific promotor Flk1, in order to demonstrate the
multifunctionalityofthefusionprotein.ThefertilizedoocytesofC57BL/6xC3H/Hemouse
fusedwithplasmidDNAcontainingtheavidinfusionproteinconstructwerereimplanted
into pseudopregnant CD1 strain females to create a transgenic mice model expressing
avidinfusion protein in the endothelium. The immunostainings for the gene modified
embryos showed a near complete endothelial expression of the fusion protein (Original
publication,Figure1AC),however,theadultoffspringoftheC57BLxCD1miceshowed
the expression only within the spleen as the Flk1 is downregulated rapidly after birth
(OriginalpublicationII,Figure1DF)(Kappeletal.,1999).Themodelwasusedtoconduct
another targeting and biodistribution study. In this experiment it was shown that the
avidinfusionproteinwasalsocapableofaccumulatingbiotinylatedligandsdirectlyfrom
the circulation and not only from the interstitial space. In practice, the transgenic mice
received USPIO intravenously with or without biotin in order to determinate particle
accumulation within the splenic veins by MRI. USPIO particles are commonly used as
contrast agents in MRI due to their magnetic susceptibility; they cause a significant
decreaseinsignalintensity,mainlyinT2*weightedimagesintheabsorbingtissues(Leeet
al.,2008,Weisslederetal.,1990).TheresultssuggestedthebUSPIObindingselectivelyinto
thesplenicvessels (Originalpublication II,Figure2andTable1).Thesignal reduction in
T2*weighted image seen after the avidinfusionprotein targeted treatmentwas equal to
approximately a tenfold difference in the amount of paramagnetic iron oxidewithin the




protein could be genetically engineered to transducer only certain type of cells or the
avidinfusionproteincouldbeexpressedundertumorordiseasespecificconditions.This
couldbeachievedbypseudotypingofthevectorwithtumorspecificantigensorbytheuse







Finally, the efficacy of avidinfusion protein based targeting was investigated in a
therapeutic context, where rats with malignant orthotopic gliomas received biotinylated
1,4,7,10tetraazacyclododecane1,4,7,10tetraacetic acid (DOTA) labelledwith 90Yttrium





for 90Y is reported to be 16 mCi/kg in rats, yet after chelation with DOTA this can be
increasedupto40mCi/kg(Martenssonetal.,2005,Mearadjietal.,2002).Theintravenous
treatment of the rats on two consecutive days with bDOTA90Y (20 mCi/kg/d) after
transductionswithSFVachievedasignificantimprovementinthesurvivaltime(45versus
37 and 33.5 days) and the hazard ratio (0.13 and 0.08) when compared to the animals
receiving bDOTA90Y without the avidinfusion protein or nontreated control animals,
respectively(Figure5andOriginalpublicationII,Figure5).Thesurvivalcouldhavebeen





lowersurvival thanthenontreatedcontrols. Itsuggests that the lowaccumulationof the
therapeuticmoleculeonlykills the cells that are themost susceptible to the treatment or
otherwiseinapoorcondition.Thisleadstothedevelopmentoftheremainingtumortissue





been administered by several kinds of routes. In addition, by using a tissuespecific
promoter,theexpressionoftheavidinfusionproteincouldbelocalizedtospecifictissues.








Figure 5. The Kaplan-Meier survival plot displaying improved survival of the rats after targeted 
radiotherapy. Graph shows the survival of control, non-targeted and targeted animals. Dotted 
line depicts the median survival. Comparison between the graphs show significant differences (p 
<  0.05). 
5.3 BIODEGRADABLE NANOPARTICLES AND TARGETED TREATMENT OF 
GLIOMA (III) 
Chemotherapy is one of the key modalities in the treatment of GBM along with
radiotherapyandsurgery.Thebenefitsofsystemicchemotherapyregimenaredueto the
broad biodistribution via the circulation reaching effectively tumor cells. However,
systemicchemotherapysuffersfromsomemajordisadvantages.First,itsuseasanefficient
treatment modality is seriously limited by severe offtarget toxicities caused by the
accumulation of the antineoplastic drug into nontumor tissues. Second, many of the
antineoplasticdrugshaveextremelypooraqueoussolubilityandhavetobeadministered
withhighlytoxicdiluentstomakethemintoasolublepharmaceuticalformulationsuitable
for systemic treatment (Singla et al., 2002).Furthermore,manyof thedrugsareavailable






of the drug. For example, TMZ is considered to cross the BBB relatively well but its
concentrationsintheCNSareonly30%oftheplasmaconcentrations(Bakeretal.,1999).
Finally, the therapeuticwindowof conventional chemotherapy is very limiteddue to its
rapidbursteffect.Anorallyadministeredorinfusedantineoplasticdrugrapidlyincreases
the body concentrations in the patient up to even toxic levels as the drug is absorbed.
However, due to the short halflives of the drugs, the effective drug concentrations
generallyrapidlydecline(Wischke,2010).
Nanomedicineisafieldofmedicalresearchthatfocusesontreatmentmodalitiesthatare
regarded as being in the nanometer scale. A novel application of nanomedicine is in
treatment of several cancers with nanoparticles, using them as nanoscale drug carriers.
Nanoparticles tend todiffer from largerparticlesnotonly in theirphysical and chemical
properties but also in their biological function and thus they hold huge potential for
improving several of the issues compromising the efficiency of the chemotherapeutical




nanoparticles canbeengineered tobiodegrade ina controlledmanner, thusavoiding the
rapid release of the drug, and in that way improving the therapeutic window of the
treatmentduetomoreconsistentdrugrelease.Inaddition,severalnanoparticletypeshave
closed, highly hydrophobic compartments, which make them suitable carriers for many
antineoplastic molecules with poor aqueous solubilities decreasing the need for toxic
diluentstobepresentinthedrugformulations.Furthermore,byappropriatenanoparticle
materialselectionorsurfacemodifications,thenanoparticlescanbeengineerednotonlyto
efficiently cross the BBB but also to be targeted directly to the tumor cells. Finally, the
surface modifications of the nanoparticles can be used to increase the bioavailability of




PEGPLAwas synthetized by melt polymerization and solution polymerization method
was used in order to synthetize bPEGPLA polymer. Polymerization of both PEGPLA
and bPEGPLA were successful. Polymers were further characterized by size exclusion
chromatography (SEC) for molecular weights and by differential scanning calorimetry
(DSC)fortheglasstransition(Tg).Inaddition,1HNMRwasusedforstructuralanalysisof
thebPEGPLApolymer.
The spectra from 1H NMR showed that the biotinylation of the polymer had been
successful (Table 11 or Original publication III, Figure 1) although due to the low
concentrationofbiotin, the characteristicpeakwasvery faint inbPEGPLAspectra.The
freeamidoprotonsignalconfirmedthe formationofacovalentbondbetweenbiotinand




polymer (3400 vs 2000 g/mol). This was done to avoid potential issues with steric
hinderance due to PEGylation of the NPs and tetrameric binding of biotin into avidin,
whichcoulddecreasethebindingefficacyoftheNPsintoavidinmoietiesatthetargeting
studies. Themolecularweight (weight average,Mw) of the polymers revealed that PEG
PLA had been synthetized in a larger quantity (40,500 vs 22,600 g/mol). However, the
number average molecular weight (Mn) indicated that there were relatively as many
monomers in both PEGPLA and bPEGPLA polymer batches (20,000 vs 19,900 g/mol,
respectively). The polydispersity index (Mw/Mn) was higher in PEGPLA (value 2.0)
whereas the bPEGPLAwas close to value of 1 (value 1.1). The polydispersity index is
related to the homogeneity of the polymer batch, where natural polymers are generally
close toavalueof1 indicating thatonlya single formof thepolymer ispresent (Atkins,
2010,Vievilleetal.,2011).Therefore,itcanbeconcludedthethebPEGPLApolymerwas
morehomogenousoruniformthanthePEGPLApointingtodifferencesbetweenthemelt
and solution polymerization methods in the reaction conditions, material ratios or
completionofthepolymerization.Theglasstransitiontemperaturevalues(Tg)ofPEGPLA
andbPEGPLAwere35°Cand15°C,respectively,whichreferstothetemperaturewhere
the polymers will change into a ‘rubberlike’ state before the temperature reaches the
melting temperature.  As the natural Tg of a PLA polymer is approximately 60 °C, the
additionofPEGchainshadsignificantlyreducedtheTgoftheformedpolymer,whichisin
linewithearlierstudies(MartinandAvérous,2001).However,Tg–stateofthepolymersin
the physiological temperatures was considered as being beneficial as there are studies
showingthatsoftnanoparticlesarenotsorapidlyendocytosedbythemacrophagesasthe
their rigid counterparts (Wang et al., 2011). In addition, the process is considered to





attributable to the longer PEGchains, and it should theoretically be higher as when
administered to a patient with ambient temperature at 3537 °C, the bPLANPs may
undergorapidchangesinthepolymerstructureanddegradeprematurely.
5.3.2Preparationandcharacterizationofnanoparticles
Nanoparticles were successfully prepared from either PEGPLA polymer (PLANPs) or
from 1:100 mixture of bPEGPLA : PEGPLA –polymers (bPLANPs) by the interfacial
deposition solvent displacement method. The antineoplastic drug, paclitaxel, was
encapsulatedintotheNPsduringthepreparation(loadedPLANPsandbPLANPs).After








properties for cancer therapy in vivo to achieve a maximal EPR effect and to evade
eliminationbytheRES(GuptaandWells,2004).Thezetapotential,particlecharge in the
specificmedium,showedanegativechargeofslightlybelow10mVforbothparticletypes
in Hepes buffered medium (pH 7.4) due to the carboxylic groups of PLA. The results




± 30 mV) is considered to be disadvantageous as there will be more particleparticle










the PEGchains were slightly longer than in the PLANPs. The amount of encapsulated
paclitaxel was measured by the extraction method where the drug concentration in the
nitrogen stream dried NPs from aqueous solution and washed lyophilized NPs, was
measuredbyHPLCafterdissolutionofequalamountofparticlesintoacetonitrile.Inboth




The drug release rate of the loaded NPs was determined using an ultracentrifugation
methodwheretheloadedNPswereincubatedin+37°Cinphosphatebufferedsalinewith
additional sodiumlaurylsulfate (SLS) to increase the solubility of the paclitaxel. At
predetermined timepoints, samples were ultracentrifuged to remove all NPs and the
paclitaxel concentrationswere then analyzed from the supernatantwithHPLC.Thedata
indicatedthat themajority(70%)of thedrughadbeenreleasedasahighburst fromthe
NPswithin the firsthour (Table11orOriginalpublication III, Figure3).After the initial





PLANPs and bPLANPs suggesting uniform polymer properties and preparation of the
NPs. The rapid release of the paclitaxel is in linewith other similar studies and can be
attributedtotheshortdiffusionaldistanceandthelargesurfacearea(Fonsecaetal.,2002).
In terms of optimal glioma therapy, a slightly slower andmore constant release profile
would have been preferable to ensure NP accumulation within the tumor as well as
minimizing the offtarget toxicity due to premature drug release. However, the release
propertiesoftheNPsarestillbetterthanTaxolformulationonitsown.

Table 11. The characteristics of the poly(lactid-acid) polymers and prepared nanoparticles as 
described in the Original Publication III, Table 1, Table 2, Figure 3 and Figure 4. 
Characteristics of the polymers and 
nanoparticles
Non-biotinylated Biotinylated 
Polymer PEG chain (g/mol) 2000 3400 
Mw (g/mol) 40.5 22.6 
Mn (g/mol) 20 19.9 
Polydispersity index (Mw/Mn) 2.0 1.1 
    
Nanoparticle Biotinylation (%) 0 1 
Tg (°C) 35 15 
Size (nm ± SD) 104.9 ± 38.6 106.8 ± 38.5 
Zeta potential (mV) 10.4 ± 0.5 10.2 ± 0.5 
Binding efficacy to streptavidin (%) 10 > 90 
Encapsulation efficacy (%)   
     washed nanoparticles 92.9 ± 3.1 93.7 ± 5.0 
     nanoparticles in suspension 93.5 ± 5.2 92.4 ± 3.9 
Drug release profile (%)   
     1 h 70 
     24 h > 90 




vitro in malignant rat glioma and hepatic carcinoma cell lines BT4C and HepG2,
respectively.Drugconcentrationsof0.150g/mlwereusedandtargetingforbPLANPs
wasachievedbyusingamethodwherebiotinylated transferrinwas first introduced into
thecells,followedbyneutralavidinbridgingandfinallyadministrationofbPLANPs.The
viability of the cells was measured 72 h after treatment with an assay based on the
mitochondrial activity of the cells. The results indicated that there was no difference in
viability between Taxol and loaded PLANPs or bPLANPs in the HepG2 cell line. The
targetedtreatmentdidnotachieveanydecrease intheviabilityof thecells,whichcanbe
explained by specific nature of theHepG2 cells.Although tumor cells are considered to
overexpress transferrin receptors, it is known that in HepG2 cells, the transferrin is
converted into apotransferrin and secreted out from the cells. Thiswas responsible for a
failureinthefirststepofthepretargetingprotocolandconsequentlyoftheentiretargeting
strategy(Stoorvogeletal.,1987).However, in themalignantratgliomacell lineBT4C, the
threesteppretargetingsignificantlyincreasedthecytotoxicityofthetreatmentatthehigher
concentrations as compared to other treatments (Original publication III, Figure 5).









protocol. In addition, the nontargeted NPs had a lower cell killing efficacy than Taxol
displaying the shielding properties of the NPs and decreased offtarget toxicity. In the
highest drug concentration group, all the treatments eradicated cellswith equal efficacy,
withtheexceptionofthetargetedbPLANPsthatstillpossessedasignificantlyimproved
efficacy. In addition to the improved cytotoxic profile of the pretargeted bPLANP
treatment,thesafetyprofileoftheNPscouldbeconsideredasbetterthanthatofTaxol.The
commercial form of paclitaxel, Taxol® has the drug dissolved in ethanol and
polyethoxylatedcastoroil(CremophorEL).CremophorELisaknownallergenmakingthe
drugunsuitable fora subpopulationof thepatients (Singlaetal., 2002).Additionally, the
formulation isknowntoaffect thepharmacokineticsofpaclitaxelbyentrapping thedrug
within inclusion micelles, seriously complicating any estimation of the drug’s
pharmacokinetics and effects in patients. However, the NPs could be filled with pure





ofPLANPsand theiruse in targetedcancer therapyusingavidinbiotin technology.The
polymerswere successfully synthetized using two separate polymerizationmethods and
NPs preparedwere found to have uniform shape, size and charge. Encapsulation of the
drug was highly efficient, although the drug release rates were inappropriately rapid.



































for improved therapeutic applications and better options. A lentiviral vector
containing the transgene expressing the avidinfusion protein capable of binding
biotinylatedmoleculeswasclonedandproducedinhightiters.Theexpressionofthe
fusion proteinwas demonstrated in vitro and in vivo.The high affinity binding of
biotinylatedligandsbytheavidinfusionproteininrepetitivemannerwasprovento
be feasible. Inaddition,no toxicitywasrelated to theuseof the lentiviralvectoror
theavidinfusionproteinandevidencewasfoundfortargetedtreatmentofGBM.

2. The avidinfusion protein was utilized in several in vivo experiments in order to
investigatethemultifunctionalityofthesystem.Theexpressionoftheavidinfusion






the rat glioma model in comparison to nontargeted treatment and controls,
highlighting the potential advantages of the avidinfusion protein in the field of
targetedtherapy.

3. A biodegradable nanocarrier for highly water insoluble drugs was first
manufactured, then characterized and finally used in an avidinbiotin based three
steptargetingprotocolforinvitrotreatmentofGBM.Thepoly(lacticacid)polymers
withPEGmodifications and optional biotin attachmentswere producedusing two
separate methods and the molecular polymer properties and structures verified.
Nanoparticles containing an insoluble antineoplastic drug were prepared
successfully from the polymers. The nanoparticles were characterized further to
ensure that they were uniform spherical particles with functional biotin on the
surface for targetingpurposes.Thenanoparticleswerenontoxic and thedrugwas
released from the particles in a rapid manner. The in vitro threestep targeting
protocol using biotinylated transferrinavidinbiotinylated nanoparticle system
improved the cell killing efficacy in comparison to nontargeted nanoparticles or a
singletreatmentwiththeantineoplasticdrug.

In summary, this thesis describes the use of targeted therapies in the treatment of




prolonged treatment protocols for GBM potentiated by the integration of the vector.
Furthermore,theuseoftheavidinfusionproteinhasinotherapplications,suchasvector
targeting or indusion as a marker gene, could be potential topics for further studies.
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of Malignant Glioma Jere T. Pikkarainen
Avidin-Biotin Technology 
and Targeted Treatment 
of Malignant Glioma
Glioblastoma multiforme is the most 
malignant brain tumor. Its treatment 
is hindered by the side-effects caused 
by the systemic chemotherapy. By 
targeted therapy, treatment is guided 
specifically into the tumor. This the-
sis aimed to develop a new targeted 
administration method using avidin-
biotin technology. Avidin-fusion 
protein was characterized in several 
targeting and imaging studies. The 
results showed that targeting offers 
significant improvements for treat-
ment strategies. 
